

CATEGORY	Coverage Indicator	Step Order	PREFERRED DRUGS	Coverage Indicator	Step Order	NON-PREFERRED DRUGS Required	PA	Comments	Criteria
----------	--------------------	------------	-----------------	--------------------	------------	------------------------------	----	----------	----------

*** PLEASE NOTE: All Generics applicable to DEL are considered PREFERRED Drugs. "BASIC" Covered Drugs are bolded with the Coverage Indicator of "MC / DEL".**

General Criteria for all PDL categories: For more information or help using the PDL, providers may call 1-888-445-0497; members should call 1-866-796-2463. To access PDL and PA materials via the internet: www.mainearepdl.org

A: Preferred Drugs: Unless otherwise specified, preferred drugs are available without prior authorization. Step order may apply for preferred drugs in some drug categories as indicated on the PDL. (See item "D" below for explanation of step order.)

B: Requests for Non-preferred Drugs: Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.

C: Adequate Drug Trials: 1. The minimum trial period for each preferred and step order drug is two weeks, unless otherwise stated within specific PDL drug categories; trials with less than a two week duration will be reviewed on a case-by-case basis; 2. A trial will not be considered valid if non-preferred products were readily available (by override, individual purchase, samples, etc.); 3. Certain drug trials, such as with preferred narcotics, may require evidence that the preferred drugs were actually tried (example: with urine drug tests); 4. Adequate trials require documentation of attempts to titrate dose of preferred agents toward desired clinical response. 5. Adequate trials include prevention/treatment of common adverse effects associated with preferred agents (example: antinausea, antipruritics, etc.)

D: Step Order: When numbers appear in the "step order" column, it means drugs in this category must be used in the order specified, with the lower numbers having preference over the higher numbers. Chart notes should be provided to confirm drug trials that do not appear in the member's MaineCare drug profile.

E: Brand Name Medication Requests: (Must be submitted on the Brand Name PA request form) According to MaineCare Benefits Manual Chapter II (80.07-5), when medically necessary covered brand-name drugs have an A-rated generic equivalent available, the most cost effective medically necessary version will be approved and reimbursed, since the brand-name and A-rated generic drugs have been determined by the FDA to be chemically and therapeutically equivalent. The Bureau does not make determinations as to whether or not a generic drug is clinically inferior or inequivalent to its brand version. This is the proper role of the FDA. Physicians should submit their reports of generic inequivalence directly to the FDA via the MEDWATCH.

F: PA requests for non- FDA Approved Indications: Decisions will be made on a case-by-case basis until the DUR committee is able to review the evidence and make a recommendation. Interim approvals and DUR recommendations for approval of a drug for a non- FDA approved indication will require a minimum of two published, peer reviewed, non contradicted, double- blind, placebo-controlled randomized clinical studies establishing both safety and efficacy.

G: Dose Consolidation Requirements: Some drugs may also be affected by dose consolidation requirements. Please see Dose Consolidation List and/or Splitting Tables provided in the PDL.

H: Trials from Multiple Drug Classes: Trial/failure/intolerance to preferred agents from multiple classes within the same category or other categories of drugs may be required prior to the approval of non-preferred agents (e.g., Cymbalta, Zofran, Elidel and others).

J: Drug-specific PA Forms: Drug-specific PA forms contain medical necessity documentation requirements and/or criteria that may not be repeated in the PDL. Drug-specific PA forms may be obtained on the web at www.mainearepdl.org.

K: PA Exemptions for Prescribers: According to MaineCare Benefits Manual Chapter II (80.07-4), providers may receive a three (3) month exemption from prior authorization requirement for certain categories of drugs when they demonstrate high compliance with the Department's PDL. The Department will notify providers in writing which drug categories are included and what dates apply to the exemption. If a provider loses his/ her exemption, members who previously were not required to obtain a PA while the prescriber was exempt will be required to do so, and criteria for approval of that medication will need to be met.

ASSORTED ANTIBIOTICS

CATEGORY	Coverage Indicator	Step Order	PREFERRED DRUGS	Coverage Indicator	Step Order	NON-PREFERRED DRUGS Required	PA	Comments	Criteria
BETA-LACTAMS / CLAVULANATE COMBO'S	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC MC MC/DEL MC MC MC MC/DEL MC MC MC MC MC MC/DEL		AMOXICILLIN AMOXIL ¹ AMPICILLIN AMOXICILLIN/POTASSIUM CLA CHEW AMOXICILLIN/POTASSIUM CLA SUSR AMOXICILLIN/POTASSIUM CLA TABS AUGMENTIN ES-600 SUSR AUGMENTIN XR TB12 BEEPEN BICILLIN L-A SUSP DICLOXACILLIN SODIUM CAPS DYNAPEN SUSR GEOCILLIN TABS OXACILLIN SODIUM SOLR PENICILLIN V POTASSIUM TICAR SOLR TIMENTIN SOLR TRIMOX UNASYN SOLR VEETIDS ZOSYN	MC/DEL MC/DEL MC MC MC/DEL MC MC MC/DEL MC MC MC MC MC MC MC MC MC MC MC MC/DEL		AMOXIL 500MG TABS AUGMENTIN ² PRINCIPEN CAPS ² PRINCIPEN SUSR		1. Amoxil 500mg tabs are non-preferred. All other Amoxil products are preferred. 2. Principen 250 mg is available without PA. 3. Chewable 125mg & 250mg and Solution 125mg/5ml and 250mg/5ml available without PA Use PA Form# 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
CEPHALOSPORINS	MC/DEL MC/DEL MC/DEL MC/DEL MC MC/DEL MC/DEL MC/DEL MC MC MC MC/DEL MC/DEL		CEFADROXIL HEMIHYDRATE CEFZOLIN SODIUM SOLR CEFTIN SUSP CEFUROXIME AXETIL TABS CEFZIL CEPHALEXIN MONOHYDRATE DURICEF SUSR FORTAZ SOLR KEFZOL SOLR MAXIPIME SOLR OMNICEF ROCEPHIN VANTIN	MC MC MC/DEL MC/DEL MC/DEL MC/DEL MC MC MC MC/DEL MC/DEL		CECLOR ¹ CEDAX CEFACTOR ¹ CEFADROXIL MONOHYDRATE TABS CEFTIN DURICEF TABS FORTAZ SOLN KEFLEX CAPS TAZICEF SOLR		1. Both brand and generic are clinically non-preferred. Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
MACROLIDES / ERYTHROMYCIN'S	MC MC/DEL MC/DEL MC MC MC MC MC/DEL MC/DEL		BIAXIN XL ¹ AZITHROMYCIN TABS CLARITHROMYCIN E.E.S. E-MYCIN TBEC ERYPED 200 SUSR ERYPED 400 SUSR ERY-TAB TBEC	MC MC/DEL MC MC MC/DEL		BIAXIN DYNABAC D5-PAK TBEC ERYPED CHEW PCE TBEC ZITHROMAX TABS		1. 7- Day supply per month w/o PA	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.

	MC MC/DEL MC/DEL MC/DEL		ERYTHROCIN STEARATE TABS ERYTHROMYCIN ZITHROMAX SUSP ZMAX				Use PA Form # 20420	
TETRACYCLINES	MC/DEL MC/DEL MC MC/DEL MC/DEL		DOXYCYCLINE HCLATE MINOCYCLINE HCL CAPS SUMYCIN TETRACYCLINE HCL CAPS VIBRAMYCIN SYRP	MC MC/DEL MC/DEL MC MC/DEL		DECLOMYCIN TABS DORYX CPEP DOXYCYCLINE MONO CAPS DYNACIN CAPS MONODOX CAPS PERIOSTAT	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
FLUOROQUINOLONES	MC MC MC MC/DEL MC		AVELOX ABC PACK TABS AVELOX SOLN AVELOX TABS CIPROFLOXACIN CIPRO XR ²	MC MC MC MC/DEL MC		CIPRO FLOXIN TABS LEVAQUIN NOROXIN TABS TEOQUIN	1. QL 3/scrip/month Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
AMINO GLYCOSIDES	MC MC/DEL MC MC/DEL		GENTAMICIN NEOMYCIN SULFATE TABS TOBI NEBU TOBRAMYCIN SULFATE SOLN					Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
ANTI-MYCObACTERIALS / ANTI TUBERCULOSIS	MC/DEL MC/DEL MC/DEL MC/DEL		ETHAMBUTOL HCL TABS MYAMBUTOL TABS MYCOBUTIN CAPS RIFAMPIN	MC		IRIMACTANE CAPS	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
ANTIMALARIAL AGENTS	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC MC/DEL		CHLOROQUINE PHOSPHATE TABS DARAPRIM TABS HYDROXYCHLOROQUINE TABS LARIAM TABS MALARONE TABS MEFLOQUINE HCL TABS QUINACRINE HCL POWD QUININE SULFATE	MC MC/DEL		ARALEN TABS PLAQUENIL TABS	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
ANTHELMINTICS	MC/DEL MC MC/DEL MC/DEL		ALBENZA TABS BILTRICIDE TABS MEBENDAZOLE CHEW STROMECTOL TABS	MC		VERMOX CHEW	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
ANTIBIOTICS - MISC.	MC MC MC MC/DEL MC MC MC/DEL MC MC/DEL		AZACTAM SOLR COLISTIMETHATE SODIUM SOLR FUROXONE TABS METRONIDAZOLE ² PENTAMIDINE ISETHIONATE SOLR PRIMSOL SOLN TRIMETHOPRIM TABS VANCOCCIN HCL VANCOMYCIN HCL	MC MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC MC/DEL MC MC		COLY-MYCIN-M SOLR FLAGYL CAPS FLAGYL TABS FLAGYL ER TBCR KETEK LORABID METRONIDAZOLE 375MG CAPS ² METRONIDAZOLE 750MG TABS ² NEBUPENT SOLR PROLOPRIM TABS TINDAMAX ¹ XIFAXAN	1. Need to fail other anti- protozoals 2. 375mg caps and 750mg tabs are non-preferred. Please use available preferred strengths(250mg & 500mg tabs) to obtain required dose without PA. Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. 1. For macrolide resistant infections when quinolones inappropriate
CARBAPENEMS				MC MC MC/DEL		INVANZ SOLR MERREM SOLR PRIMAXIN		Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
LINCOSAMIDES / OXAZOLIDINONES / LEPROSTATICS	MC/DEL MC/DEL MC/DEL MC		CLEOCIN SOLN CLEOCIN SUSR CLINDAMYCIN HCL 150CAPS DAPSONE TABS	MC/DEL MC/DEL MC/DEL MC/DEL		CLEOCIN CAPS CLINDAMYCIN HCL 300CAPS ² ZYVOX SUSR ZYVOX TABS	1. Use multiple 150's for Clindamycin instead of 300's. Zyvox: use PA Form # 30820 Others: use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. For Zyvox, please see the criteria listed in the Zyvox PA form.
ANTI INFECTIVE COMBO'S - MISC.	MC/DEL MC/DEL MC/DEL MC/DEL		ERYTHROMYCIN/SULF SUSR SEPTRA/DS TABS SULFAMETHOXAZOLE/TRIMETH TRIMETHOPRIM/SULFAMETHOXA	MC MC		ALINIA* BACTRIM DS TABS	* Alinia is preferred for children less than 12 years of age. Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
ANTI - FUNGALS								
ANTIFUNGALS - ASSORTED	MC MC/DEL MC MC MC MC/DEL MC/DEL		ANCOBON CAPS FLUCONAZOLE ¹ GRIFULVIN GRISEOFULVIN ULTRAMICROSI TABS GRIS-PEG TABS KETOCONAZOLE TABS NYSTATIN	MC/DEL MC MC MC MC/DEL MC	5 5 5 6 8 8	LAMISIL TABS SPORANOX SOLN ² SPORANOX PULSEPAK CAPS ³ SPORANOX CAPS ² DIFLUCAN ¹ NIZORAL TABS	1. QL--1/every 7-day period (150mg only). 2. Sporanox QL 300cc/month with PA. See quantity limit table. 3. Sporanox QL 30/month with PA. See quantity limit table. Non-preferred products must be used in specified	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. The other criteria are listed on the Antifungal PA form including the required proof of a non-cosmetic fungal infection.

	MC/DEL		VFEND TABS						step order. Continue to use Anti-Fungal PA form for non-preferred products. Use PA Form # 10120		
ANTI - VIRALS											
ANTIRETROVIRALS	MC/DEL MC/DEL MC/DEL MC MC/DEL MC/DEL MC MC/DEL MC MC/DEL MC MC/DEL MC MC/DEL MC MC/DEL MC MC/DEL MC MC/DEL		AGENERASE CAPS APTIVUS COMBIVIR TABS CRIXIVAN CAPS EMTRIVA EPIVIR / HBV EPZICOM FORTOVASE CAPS HIVID TABS INVIRASE CAPS KALETRA LEXIVA NORVIR RESCRIPTOR TABS RETROVIR REYATAZ SUSTIVA TRIZIVIR TABS TRUVADA VIDEX / EC VIRACEPT TABS VIRAMUNE TABS VIREAD TABS ZERIT ZIAGEN TABS	MC/DEL MC/DEL					DIDANOSINE FUZEON	Fuzeon use PA Form # 10620 Turvada use PA form #20420	Please refer to the criteria listed on the Fuzeon PA form.
CYTO-MEGALOVIRUS AGENTS	MC/DEL MC		GANCICLOVIR VALCYTE TABS	MC				CYTOVENE CAPS	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.	
IMMUNE SERUMS											
IMMUNE SERUMS			HYPERRHO INJ								
HEPATITIS AGENTS											
HEPATITIS C AGENTS	MC/DEL MC/DEL MC/DEL		PEG-INTRON KIT REBETRON KIT REBETOL CAPS	MC/DEL MC/DEL MC/DEL MC	8 8 8 8			COPEGUS TABS PEGASYS KIT PEGASYS SOLN RIBAVIRIN CAPS	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved (in step order), unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.	
HEPATITIS AGENTS - MISC.				MC				ACTIMMUNE	Use PA Form # 20420	Approved for chronic granulomatous disease, osteopetrosis and idiopathic pulmonary fibrosis.	
HEPATITIS B ONLY	MC		HEPSERA TABS	MC				BARACLUDE			
HERPES AGENTS	MC/DEL MC/DEL		ACYCLOVIR VALTREX TABS	MC/DEL MC/DEL				FAMVIR TABS ZOVIRAX	Must fail Acyclovir and Valtrex before non-preferred products. Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved (in step order), unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.	
INFLUENZA AGENTS	MC/DEL MC MC/DEL MC/DEL		AMANTADINE RELENZA DISKHALER AEPB RIMANTADINE HCL TABS TAMIFLU ¹	MC/DEL MC MC				FLUMADINE TABS FLUMIST ²	1. Tamiflu 10 caps or 60cc's per month. 2. Flumist Use Form # 10610. Others Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved (in step order), unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.	
RSV PROPHYLAXIS											
RSV PROPHYLAXIS				MC MC				RESPIGAM SYNAGIS	Use PA Form # 30120	Please see the criteria listed on the Synagis PA form.	
MS TREATMENTS											
MULTIPLE SCLEROSIS AGENTS				MC MC/DEL MC MC/DEL	5 5 5 6			AVONEX KIT BETASERON SOLR REBIF SOLN COPAXONE	Established users grandfathered. Must follow specified step order. Use PA Form # 20430	Non-Preferred drugs must be tried in step-order and failed due to lack of efficacy or intolerable side effects before lower ranked non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.	
ASSORTED NEUROLOGICS											
NEUROLOGICS - MISC.	MC MC/DEL MC		MESTINON ORAP TABS PROSTIGMIN TABS	MC MC/DEL				BOTOX MYOBL0C ¹	1. Myobloc approval will be limited to Cervical Dystonia. Use PA Form #10210	Failed/did not tolerate therapeutic trials to muscle relaxants, unless contraindicated, including but not limited to baclofen, cyclobenzaprine, orphenadrine, Skelaxin, and tizanidine.	
STEROIDS											
GLUCOCORTICOID/ MINERALOCORTICOID	MC MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL		CELESTONE SUSP CORTEF 5 CORTISONE ACETATE TABS DELTASONE TABS DEPO-MEDROL SUSP DEXAMETHASONE	MC MC MC/DEL MC/DEL MC MC				CORTEF 10 and 20 TABS DECADRON TABS FLORINEF TABS MEDROL TABS MEDROL DOSEPAK TABS PEDIAPRED LIQD	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.	

	MC/DEL		ENTOCORT EC CP24	MC		PREDNISON INTENSOL CONC		
	MC/DEL		FLUDROCORTISONE ACETATE TABS	MC		PRELONE SYRP		
	MC/DEL		HYDROCORTISONE	MC		STERAPRED TABS		
	MC		KENALOG					
	MC/DEL		METHYLPREDNISOLONE TABS					
	MC		ORAPRED SOLN					
	MC/DEL		PREDNISOLONE					
	MC/DEL		PREDNISON					
	MC/DEL		SOLU-CORTEF SOLR					
	MC/DEL		SOLU-MEDROL SOLR					

HORMONE REPLACEMENT THERAPIES

ANDROGENS / ANABOLICS	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC MC/DEL MC MC		ANDRODERM PT24 ANDROID CAPS DANAZOL CAPS DEPO-TESTOSTERONE OIL FLUOXYMESTERONE TABS TESTODERM TESTOSTERONE PROPIONATE TESTRED CAPS WINSTROL TABS	MC MC/DEL MC MC MC/DEL MC/DEL		ANDRO LA 200 OIL ANDROGEL PACK DELATESTYL OIL HALOTESTIN TABS METHITEST TABS OXANDRIN TABS ¹	Use PA Form # 20420 1. Non-preferred effective 12.01.05. Use the Oxandrin PA Form #20600	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. Additionally, laboratory evidence of a testosterone deficiency must be supplied. One of each dosage form should be tried (tablet, injection, and topical)
ESTROGENS - PATCHES	MC/DEL MC/DEL		ESTRADERM PTTW VIVELLE PTTW	MC/DEL MC/DEL MC/DEL MC MC/DEL	5 8 8 8 8	ESTRADIOL PTWK ALORA PTTW CLIMARA PTWK ESCLIM PTTW VIVELLE-DOT PTTW	All patches are non-preferred products (require PA). Products must be used in specified step order. Use PA Form # 20420	Approved for failures on multiple oral estrogen agents after 90 day trials or if unable to swallow any oral medication.
ESTROGENS - TABS	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL		CENESTIN TABS DELESTROGEN OIL ESTRADIOL ESTROPIPATE TABS MENEST TABS PREMARIN TABS	MC/DEL MC MC/DEL MC		ESTRACE TABS ESTRATAB TABS OGEN TABS ORTHO-EST TABS	Must fail preferred products before non-preferred products. Use PA Form # 20420	Preferred drugs must be tried for at least 90 days and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
ESTROGEN COMBO'S	MC/DEL MC/DEL		PREMPHASE TABS PREMPRO TABS	MC/DEL MC/DEL MC/DEL MC/DEL		ACTIVELLA TABS COMBIPATCH PTTW FEMHRT 1/5 TABS ORTHO-PREFEST TABS SYNTEST H.S. TABS	Must fail Premphase and Prempro products before non-preferred products. Use PA Form # 20420	Preferred drugs must be tried for at least 90 days and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
PROGESTINS	MC/DEL MC/DEL MC		MEDROXYPROGESTERONE ACETA ² NORETHINDRONE ACETATE TABS ¹ PROGESTERONE POWD	MC/DEL MC MC/DEL MC/DEL MC/DEL		AYGESTIN TABS CYCRIN TABS PROMETRIUM 100MG CAPS ¹ PROMETRIUM 200MG ¹ PROVERA TABS	1. PA approvals will require two 100 mg caps instead of one 200mg. 2. Must fail Medroxyprogesterone and Norethidrone products before non-preferred products. Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.

CONTRACEPTIVES

CONTRACEPTIVES - PROGESTIN ONLY	MC		ORTHO MICRONOR TABS	MC/DEL MC/DEL MC/DEL MC/DEL		CAMILA TABS NORA-BE TABS NOR-OD TABS OVRETTE 28 TABS	If member experienced adverse reactions, consider using Oral Contraceptives from other groups. Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
CONTRACEPTIVES - INJECTABLE	MC/DEL		DEPO-PROVERA SUSP	MC/DEL MC/DEL		LUNELLE SUSP MEDROXYPROGESTERONE ACETATE IM	Use PA Form # 20420	The preferred drug must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
CONTRACEPTIVE - EMERGENCY	MC/DEL		PLAN - B ¹				1. Allowed 4 tablets per 30 days without PA	
CONTRACEPTIVES - PATCHES/ VAGINAL PRODUCTS	MC		ORTHO EVRA PTWK ^{1,2}	MC/DEL		NUVARING RING	1.No PA required for users less than 21 years of age. 2. The FDA has issued a public health warning of the potentials for increased exposure to estrogen with Ortho Eva use, possibly up to 60% estrogen exposure Use PA Form # 20420	Approved if adequate clinical reason given why patient unable to comply with other preferred agents including long acting injectable.
CONTRACEPTIVES - MONOPHASIC COMBINATION OIC'S	MC/DEL MC/DEL MC/DEL MC/DEL		ALESSE-28 TABS DEMULEN 1/35-28 TABS DEMULEN 1/50-28 TABS DESOGEN TABS	MC/DEL MC/DEL MC/DEL MC/DEL		APRI TABS AVIANE TABS BREVICON-28 TABS CRYSSELLE-28 TABS	Loestrin FE and FE 1/20 are grandfathered for established users. If member experienced adverse reactions, consider using Oral	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.

	MC/DEL MC/DEL		ACTOS 15MG TABS ¹ ACTOS 45MG TABS ¹				preferred without PA if patient on insulin or sulfonylurea or metformin. Avandia non-preferred as monotherapy. 2. Actos 30mg - use two 15mg instead. Use PA Form # 20420	on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
DIABETIC - ALPHAGLUCOSIDASE	MC/DEL		GLYSET TABS	MC		PRECOSE TABS	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
DIABETIC - SULFONYLUREA / BIGUANIDE	MC/DEL		GLYBURIDE/METFORMIN	MC MC		GLUCOVANCE TABS METAGLIP TABS	Use individual ingredients. Use PA Form # 20420	Approved for patients failing to achieve good diabetic control with maximal doses of individual components.
DIABETIC - MEGLITINIDES	MC/DEL		STARLIX TABS	MC/DEL		PRANDIN TABS	Use PA Form # 20420	Preferred drugs from other diabetic sub-categories must be tried and failed due to lack of inadequate diabetic control or intolerable side effects before non-preferred drug will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
THYROID								
THYROID HORMONES	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL		ARMOUR THYROID TABS CYTOMEL TABS LEVOTHROID TABS LEVOTHYROXINE SODIUM TABS LEVOXYL TABS THYROID TABS THYROLAR UNITHROID TABS	MC MC		LEVOTHYROXINE SODIUM SOLR SYNTHROID TABS ¹	Use Pa Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
ANTITHYROID THERAPIES	MC/DEL MC/DEL		METHIMAZOLE TABS PROPYLTHIOURACIL TABS	MC/DEL		TAPAZOLE TABS	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
OSTEOPOROSIS								
OSTEOPOROSIS	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL		ACTONEL TABS FOSAMAX SOLN ² FOSAMAX TABS ² FOSAMAX PLUS D ² MIACALCIN SOLN	MC MC/DEL MC/DEL MC MC		AREZIA SOLR BONIVA DIDRONEL TABS EVISTA TABS ¹ FORTEO	1. Approval only requires failure of Fosamax or Actonel. Use PA Form # 20420 2. Quantity Limits Apply	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
CALCIMIMETIC AGENTS								
CALCIMIMETIC AGENTS				MC		SENSIPAR	Use PA Form # 30115	Baseline PTH, Ca, and phosphorous levels are required and initial approvals will be limited to 3 months. Subsequent approvals will require additional levels being done to assess changes. Will not approve if baseline Ca is less than 8.4.
GROWTH HORMONE								
GROWTH HORMONE				MC/DEL MC/DEL MC/DEL MC MC/DEL MC	5 5 6 8 8 8	GENOTROPIN TEV-TROPIN NUTROPIN HUMATROPE SOLR NORDITROPIN CARTRIDGE SOLN SAIZEN SOLR	Products must be used in specified step order. Use PA Form # 10710	See Growth Hormone PA form for criteria. Step-order will still apply unless clinical contraindication supplied.
SOMATOSTATIC AGENTS	MC/DEL		SANDOSTATIN					
GROWTH HORMONE ANTAGONISTS								
GH ANTAGONISTS				MC		SOMAVERT	Use PA Form # 10710	Approved for acromegaly patients failing surgery/radiation/drug therapy including bromocriptine and sandostatatin.
URINARY INCONTINENCE								
VASOPRESSINS			DESMOPRESSIN TABS	MC/DEL MC/DEL MC MC/DEL MC/DEL	5 6 6 8 8	DDAVP TABS DDAVP SOLN DESMOPRESSIN SPRAY DESMOPRESSIN ACETATE SOLN STIMATE SOLN*	Products must be used in specified step order. Nocturnal enuresis patients will be encouraged to periodically attempt stopping DDAVP. Use Pa Form # 20420	Approved for central diabetes insipidus and for nocturnal enuresis. For nocturnal enuresis- must be over 6 years old, must fail an adequate trial of alarm training (higher success rate, lower relapse rate) and must periodically attempt weaning (at 6 month intervals). * Patients with a diagnosis of hemophilia or Von Willebrands disease will be exempt from prior authorization.
ANTISPASMODICS	MC/DEL MC		OXYBUTYNIN URISPAS TABS	MC/DEL MC/DEL MC/DEL		CYSTOSPAZ TABS DETROL TABS DITROPAN	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
ANTISPASMODICS - LONG ACTING	MC/DEL MC MC/DEL MC		DETROL LA CP24 DITROPAN XL TBCR ENABLEX ¹ VESICARE ¹	MC/DEL MC		OXYTROL SANCTURA	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. 1. Vesicare 5mg and Enablex 7.5mg maximum doses if given with drugs known to be significant CYP3A4 inhibitors. (Ketoconazole, Sporanox, Erythromycin, Biaxin, Nefazodone, Nelfinavir, and Rilonavir)
CHOLINERGIC	MC/DEL		URECHOLINE					
METABOLIC MODIFIER								
HERED. TYROSINEMIA				MC		ORFADIN	Use PA Form # 20420	Approved for Type 1 hereditary tyrosinemia patients. Must include laboratory evidence of dx at first PA.
ANTIHYPERTENSIVES / CARDIAC								
CARDIAC GLYCOSIDES	MC/DEL MC/DEL MC/DEL MC/DEL		DIGITEK TABS DIGOXIN LANOXICAPS LANOXIN					
ANTIANGINALS--Isosorbide Di-	MC/DEL		ISOSORBIDE MONONITRATE TABS	MC		DILATRATE SR CP/CR	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered

Nitrate/ Mono-Nitrates	MC/DEL		ISOSORBIDE MONONITRATE ER	MC MC/DEL MC MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC	ISORDIL TABS ISORDIL TITRADOSE TABS ISOSORBIDE DINITRATE SUBL ISOSORBIDE DINITRATE TABS ISOSORBIDE DINITRATE CR TBCR ISOSORBIDE DINITRATE ER TBCR ISOSORBIDE DINITRATE TD TBCR IMDUR TB24 ISMO TABS MONOKET TABS		on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
NITRO - OINTMENT/CAP/PCR	MC MC/DEL MC MC		NITROBID OINT NITROGLYCERIN CPR NITROL OINT NITRO-TIME CPR				
NITRO - PATCHES	MC/DEL MC/DEL MC/DEL MC/DEL	1 1 1 3	NITROGLYCERIN PT24 NITREK PT24 NITRO-DUR PT 24 0.8MG MINITRAN PT24	MC MC/DEL	NITRODISC PT24 NITRO-DUR PT24	At least 2 step 1's and step 3 of the preferred products must be used in specified order or PA will be required. Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
NITRO - SUBLINGUAL/ SPRAY	MC MC/DEL MC/DEL		NITROLINGUAL AERS NITROSTAT SUBL NITROTAB SUBL	MC MC/DEL	NITROLINGUAL SOLN NITROQUICK SUBL	Use Pa Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
BETA BLOCKERS - NON SELECTIVE	MC/DEL MC/DEL MC MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL		COREG TABS INDERAL LA CPR LEVATOL TABS NADOLOL TABS PINDOLOL TABS PROPRANOLOL HCL SOLN ¹ PROPRANOLOL HCL TABS ¹ SOTALOL HCL TABS TIMOLOL MALEATE TABS	MC/DEL MC MC/DEL MC/DEL MC MC/DEL	BETAPACE TABS BETAPACE AF TABS CORCARD TABS INDERAL TABS INNOPRAN XL PROPRANOLOL HCL LA CPR	1. Recommend using BID since its effects do not last 24 hours. Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
BETA BLOCKERS - CARDIO SELECTIVE	MC/DEL MC/DEL MC MC/DEL MC/DEL		ACEBUTOLOL HCL CAPS ATENOLOL TABS ¹ BETAXOLOL HCL TABS BISOPROLOL FUMARATE TABS METOPROLOL TARTRATE TABS ¹ TOPROL XL TB24	MC MC/DEL MC MC/DEL MC/DEL	KERLONE TABS LOPRESSOR TABS SECTRAL CAPS TENORMIN TABS ZEBETA TABS	1. Recommend using Atenolol (and metoprolol) BID since its effects do not last 24 hours. Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
BETA BLOCKERS - ALPHA / BETA	MC/DEL		LABETALOL HCL TABS	MC	TRANDATE TABS	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
CALCIUM CHANNEL BLOCKERS- Amlodipines, Bepiridil, Diltiazems, Felodipines, Isradipines, Nifedipines, Nisoldipine, and Verapamils	MC/DEL MC MC MC/DEL MC/DEL MC/DEL MC MC/DEL MC/DEL MC/DEL	1 1 1 1 1 1 4 4 4 4	NORVASC TABS CARDIZEM LA TB24 DILTIA XT CP24 DILTIAZEM HCL ER CP24 DILTIAZEM HCL XR CP24 DILTIAZEM CD 300MG CP24 DILTIAZEM CD 360MG CP24 CARTIA XT CP24 DILTIAZEM CD CP24 DILTIAZEM HCL ER CP24 DILTIAZEM XR CP24	MC MC MC/DEL MC/DEL MC MC/DEL MC/DEL	5 6 7 8 8 8 8 8 8	DILACOR XR CP24 TAZTIA TIAZAC CP24 CARDIZEM TABS CARDIZEM CD CP24 CARDIZEM SR CP12 DILTIAZEM HCL TABS DILTIAZEM HCL ER CP12	Products must be used in specified order or PA will be required. Just write "Cardizem LA" or "Diltiazem 24-hour" and the pharmacy will use a preferred long acting diltiazem that does not require PA. Use PA Form # 20420
				MC/DEL	PLENDIL TB24	Use PA Form # 20420	Other Preferred calcium channel blockers must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
				MC MC	DYNACIRC CAPS DYNACIRC CR TBCR ¹	Use PA Form # 20420 1. Established users will be grandfathered	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
				MC/DEL MC/DEL MC/DEL	CARDENE CAPS CARDENE SR CPR NICARDIPINE HCL CAPS	Use PA Form # 20420	Other Preferred calcium channel blockers must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL		AFEDITAB CR NIFEDIAC CC NIFEDICAL XL TBCR NIFEDIPINE TBCR NIFEDIPINE CAPS NIFEDIPINE ER TBCR	MC MC/DEL MC	ADALAT CC TBCR NIFEDIPINE CAPS PROCARDIA CAPS	Established users of Adalat CC are grandfathered.	Preferred drug must be tried and failed in step order due to lack of efficacy or intolerable side effects before non-preferred drugs in step order will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
	MC		SULAR TB24		PROCARDIA XL TBCR	Use PA Form # 20420	
	MC/DEL MC/DEL MC/DEL	1 1 1	VERAPAMIL HCL CR TBCR VERAPAMIL HCL ER TBCR VERAPAMIL HCL SR TBCR	MC/DEL MC/DEL MC/DEL	CALAN TABS CALAN SR TBCR COVERA-HS TBCR	Products must be used in specified order or PA will be required. Just write "Verapamil 24-hour" and the	Preferred drugs must be tried and failed (in step-order) due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.

	MC	1	VERELAN PM CP24	MC MC/DEL MC MC MC	ISOPTIN-SR VERAPAMIL HCL ER CP24 VERAPAMIL HCL SR CP24 VERAPAMIL HCL TABS VERELAN CP24	pharmacy will use a preferred long acting generic that does not require PA. Use PA Form # 20420	
ANTIARRHYTHMICS	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC MC/DEL MC/DEL MC MC/DEL		AMIODARONE MEXILETINE NORPACE PROCAINAMIDE PROCANBID CR PROPAPENONE QUINAGLUTE QUINIDINE GLUCONATE QUINIDINE SULFATE RYTHMOL TAMBOCOR	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC MC/DEL MC/DEL MC MC/DEL	CORDARONE DISOPYRAMIDE FLECAINIDE MEXITIL PACERONE QUINIDEX TIKOSYN ¹	1. Prescription must be written by Cardiologist. Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
ACE INHIBITORS	MC/DEL MC/DEL MC/DEL MC/DEL MC		CAPTAPRIL TABS BENAZEPRIL HCL ENALAPRIL MALEATE TABS LISINAPRIL TABS MONOPRIL TABS	MC MC/DEL MC/DEL MC/DEL MC MC/DEL MC/DEL MC/DEL MC/DEL MC MC/DEL	5 MAVIK TABS 5 ACCUPRIL TABS 8 ACEON TABS 8 ALTACE CAPS 8 CAPOTEN TABS 8 FOSINOPRIL SODIUM 8 LOTENSIN TABS 8 MOEXIPRIL 8 PRINIVIL TABS 8 UNIVASC 8 VASOTEC TABS 8 ZESTRIL TABS	Non-preferred products must be used in specified order. Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs (in step-order) will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. Non-preferred products are subject to step-order requirements unless clinical circumstances warrant exception.
ANGIOTENSIN RECEPTOR BLOCKER	MC MC/DEL MC/DEL MC/DEL MC/DEL MC		AVAPRO TABS BENICAR TABS COZAAR TABS DIOVAN MICARDIS TABS TEVETEN TABS	MC/DEL	ATACAND TABS	Preferred products only available without PA if patient on diabetic therapy or prior ACE therapy. Use PA Form # 20420	The initial criteria to use any ARB is that the member must have failed ACE inhibitors (such as due to coughing) in the past or must currently be actively treated for diabetes and Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
ANTIHYPERTENSIVES - CENTRAL	MC/DEL MC/DEL MC/DEL MC/DEL MC MC/DEL MC/DEL MC/DEL MC/DEL		CATAPRES-TTS CLONIDINE HCL TABS GUANFACINE HCL TABS HYDRALAZINE HCL TABS HYLOREL TABS METHYLDOPA TABS MINOXIDIL TABS PRAZOSIN HCL CAPS RESERPINE TABS	MC/DEL MC MC MC MC/DEL	CATAPRES TABS GUANABENZ ACETATE TABS ISMELIN TABS MINIPRESS CAPS TENEX TABS	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
ACE INHIBITORS AND CA CHANNEL BLOCKERS	MC/DEL MC		LOTREL CAPS TARKA TBCR	MC/DEL	LEXCEL TBCR	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
ACE AND THIAZIDE COMBO'S	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL		BENAZEPRIL HCL/HYDROCHLOR CAPTOPRIL/HYDROCHLOROTHIA ENALAPRIL MALEATE/HCTZ TABS LISINAPRIL-HCTZ TABS UNIRETIC TABS	MC/DEL MC MC/DEL MC MC/DEL MC MC/DEL	ACCURETIC TABS CAPOZIDE TABS LOTENSIN HCT TABS MONOPRIL HCT TABS PRINZIDE TABS VASERETIC TABS ZESTORETIC TABS	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
BETA BLOCKERS AND DIURETIC COMBO'S	MC/DEL MC/DEL MC/DEL		ATENOLOL/CHLORTHALIDONE BISOPROLOL FUMARATE/HCTZ PROPRANOLOL/HCTZ	MC MC/DEL MC/DEL MC MC MC/DEL	CORZIDE TABS INDERIDE 40/25 TABS LOPRESSOR HCT TABS TENORETIC TIMOLIDE 10/25 TABS ZIAC TABS	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
ARB'S AND DIURETICS	MC MC/DEL MC/DEL MC/DEL MC/DEL MC		AVALIDE TABS BENICAR HCT DIOVAN HCT TABS HYZAAR TABS MICARDIS HCT TABS TEVETEN HCT TABS	MC/DEL	ATACAND HCT TABS	Preferred products only available without PA if patient on diabetic therapy or prior ACE therapy. Use PA Form # 20420	Same initial criteria as the ARB class and Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
DIURETICS	MC/DEL MC MC/DEL MC/DEL MC/DEL MC/DEL MC		ACETAZOLAMIDE TABS AMILORIDE HCL BUMETANIDE CHLOROTHIAZIDE TABS CHLORTHALIDONE TABS EDECRIN TABS	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL	ALDACTAZIDE TABS ALDACTONE TABS BUMEX TABS DEMADEX TABS DIAMOX DIURIL	1. Multiples of Spironolactone 25 mg are cheaper than 50 mg strength. Inspa will be approved for severe breast tenderness and male gynecomastia.	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.

	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC		FUROSEMIDE HYDROCHLOROTHIAZIDE INDAPAMIDE TABS METHAZOLAMIDE TABS METHYLOTHIAZIDE TABS SPIRONOLACTONE 25MG TABS SPIRONOLACTONE/HYDRO TORMEMIDE TABS TRIAMTERENE/HCTZ ZAROXOLYN TABS	MC/DEL MC MC MC/DEL MC MC/DEL MC MC MC MC/DEL	DYAZIDE CAPS ENDURON TABS INSPIRA LASIX TABS LOZOL TABS MAXZIDE MICROZIDE CAPS MIDAMOR TABS MODURETIC 5-50 TABS NAQUA TABS NATURETIN TABS SPIRONOLACTONE 50MG ¹		Use PA Form # 20420	
CCB / LIPID	MC/DEL		CADUET					
LIPID DRUGS								
CHOLESTEROL - BILE SEQUESTRANTS	MC/DEL MC/DEL		CHOLESTYRAMINE COLESTID	MC/DEL MC MC/DEL	PREVALITE QUESTRAN WELCHOL TABS		Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
CHOLESTEROL - FIBRIC ACID DERIVATIVES	MC/DEL MC MC/DEL MC		GEMFIBROZIL TABX TRIGLIDE NIASPAN TRICOR	MC MC MC	ANTARA LIPID LOFIBRA		Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
CHOLESTEROL - HGM COA + ABSORB INHIBITORS	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC MC MC/DEL		ADVICOR TBCR ALTOPREV TB 24 CRESTOR LIPITOR TABS LESCOL CAPS LESCOL XL TB24 LOVASTATIN TABS VYTORIN ZETIA TABS ¹ ZOCOR TABS	MC/DEL MC MC/DEL	MEVACOR TABS PRAVACHOL TABS PRAVIGARD		1. Zetia available w/OPA as addition to Zocor 80mg, Lipitor 80mg, or Crestor 40mg. Zetia will also be approved with a PA as add on for patients at maximally tolerated doses of statins. Zocor patients trying to use Zetia must use Vytorin instead. Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. Zetia will be approved for patients unable to tolerate all other therapies or unable to achieve cholesterol goal with maximally tolerated dose of most potent statins.
PULMONARY ANTI-HYPERTENSIVES								
PULMONARY ANTI-HYPERTENSIVES				MC/DEL MC	FLOLAN TRACLEER		Use PA Form # 20420	Flofan and Tracleer will be approved after the dx of pulmonary hypertension is confirmed.
IMPOTENCE AGENTS								
IMPOTENCE AGENTS					9 9 9 9 9 9 9	CAVERJECT CIALIS EDEX LEVITRA MUSE VIAGRA YOHIMBINE HCL TABS	As of January 1, 2006, per CMS (federal govt.), impotence agents are no longer covered.	
ANTI-EMETOGENICS								
ANTIEMETIC - ANTICHOLINERGIC / DOPAMINERGIC	MC/DEL MC/DEL MC/DEL MC/DEL MC		MECLIZINE HCL TABS PHENERGAN SUPP PHENERGAN FORTIS SYRP PROMETHAZINE SUPP PROMETHAZINE TRANSDERM-SCOP PT72	MC MC/DEL MC/DEL MC/DEL MC	ANTIVERT TABS PHENERGAN SOLN PHENERGAN TABS PROMETHEGAN SUPP TORECAN TABS		Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
ANTIEMETIC - 5-HT3 RECEPTOR ANTAGONISTS/ SUBSTANCE P NEUROKININ	MC MC/DEL MC/DEL MC/DEL MC/DEL		EMEND MARINOL CAPS ZOFRAN SOLN* ZOFRAN TABS* ZOFRAN ODT TBPDP*	MC MC MC/DEL	ALOXI ANZEMET TABS KYTRIL		*See quantity limit table. Zofran: use PA Form # 30810 Others: use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. * Zofran limits still apply as listed on the Zofran PA form for covered indications including chemotherapy, radiotherapy, post operative nausea & vomiting and hyperemesis gravidarum. Other medical indications will be approved or denied on a case by case basis. Hyperemesis and other medical indications approved are still subject to failure of multiple preferred antiemesis drugs.
NON-SEDATING ANTIHISTAMINES / DECONGESTANTS								
ANTIHISTAMINES - NON-SEDATING	MC MC MC MC/DEL		ALAVERT TABS ¹ CLARITIN ALLERGY (OTC) ¹ CLARITIN SYRP (OTC) ² TAVIST ND (OTC) ¹	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL	5 5 5 8 8 9	CLARINEX TABS ² CLARINEX SYR ² ZYRTEC ³ ALLEGRA CLARITIN ² FEXOFENADINE	1. Preferred drugs are OTC loratidines. 2. Claritin OTC syrup does not require a PA. 3. Clarinex and Zyrtec syrup <6 yr w/o PA. Must fail Clarinex Tabs and Zyrtec products before moving to next step product without PA Pseudoephedrine is available with prescription. Use PA Form # 20530	Preferred drug must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved (in step order), unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. No combination product with decongestant will be approved since pseudoephedrine available without PA.

ALLERGY / ASTHMA THERAPIES

ANTIASTHMATIC - ANTICHOLINERGICS - INHALER	MC/DEL MC		ATROVENT AERS ATROVENT HFA	MC		SPIRIVA ¹	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. 1. FEV ₁ <= 50% or COPD hospitalization within 6 months due to Atrovent failure.
ANTIASTHMATIC - ANTICHOLINERGICS - NEBULIZER	MC/DEL		IPRATROPIUM BROMIDE SOLN	MC		ATROVENT SOLN	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
ANTIASTHMATIC - ANTIINFLAMMATORY AGENTS	MC/DEL MC/DEL MC/DEL		CROMOLYN SODIUM NEBU INTAL AERS TILADE AERS	MC/DEL		XOLAIR ²	1. Need max inhaled steroids and written by pulmonary or allergy specialist. Use PA Form # 20420	Xolair approval will require suboptimal response to maximal doses of inhaled steroid as evidenced by asthmatic ER/Hospital admissions and Allergy/Pulmonary specialist management.
ANTIASTHMATIC - NASAL STEROIDS	MC/DEL MC/DEL MC MC/DEL MC	1 1 4 4 4	FLONASE SUSP ¹ NASONEX SUSP ¹ BECONASE AERS BECONASE AQ INHA NASAREL SOLN	MC/DEL MC MC/DEL MC MC/DEL MC MC		FLUNISOLIDE SOLN NASACORT AERS NASACORT AQ AERS RHINOCORT AERO RHINOCORT AQUA SUSP TRI-NASAL SOLN VANCENASE POCKETHALER AERS	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
ANTIASTHMATIC - NASAL MISC.	MC/DEL		NASALCROM	MC MC MC/DEL		ATROVENT NASAL SOL IPRATROPIUM NASAL SOL ¹ ASTELIN	1. Ipratropium will be approved if submitted with documentation supporting use of CPAP machine. Use PA Form # 20420	Approved if patient fails on non-sedating antihistamines and steroid nasal sprays. Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
ANTIASTHMATIC - BETA - ADRENERGICS	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL		ALBUTEROL FORADIL AEROLIZER CAPS MAXAIR METAPROTERENOL SEREVENT TERBUTALINE SULFATE TABS XOPENEX HFA	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC MC MC/DEL		ACCUNEUB NEBU ALUPENT AERP BRETHINE PROVENTIL PROVENTIL HFA AERS VENTOLIN AERS VENTOLIN HFA AERS VOLMAX TBCR VOSPIRE ER TB12 XOPENEX NEBU ²	1. Xopenex users with prior asthma hospitalization due to albuterol nebulizer failure will be grandfathered. 2. Quantity Limit: 12 cc/day. Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
ANTIASTHMATIC - ADRENERGIC COMBINATIONS	MC/DEL		ADVAIR DISKUS MISC					Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. Duoneb components are available separately without PA.
ANTIASTHMATIC - ADRENERGIC ANTICHOLINERGIC	MC/DEL		COMBIVENT AERO	MC/DEL		DUONEB SOLN ¹	1. Please use preferred individual ingredients Albuterol and Ipratropium. Use PA Form # 20420	
ANTIASTHMATIC - XANTHINES	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL		AMINOPHYLLINE TABS THEOCHRON TB12 THEOLAIR-SR TB12 THEOPHYLLINE ELIX THEOPHYLLINE SOLN THEOPHYLLINE ER CP12 THEOPHYLLINE ER TB12 UNIPHYL TBCR	MC MC MC MC/DEL MC MC/DEL MC		QUIBRON CAPS QUIBRON-T TABS QUIBRON-T/SR TB12 THEO-24 CP24 THEOLAIR TABS THEOPHYLLINE CR TB12 T-PHYL TB12	Use PA Form 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
ANTIASTHMATIC - STEROID INHALANTS	MC/DEL MC/DEL MC/DEL MC MC/DEL MC/DEL MC MC		AEROBID AERS ASMANEX AZMACORT AERS BECLOVENT AERS FLOVENT PULMICORT SUSP ¹ QVAR AERS VANCERIL AERS	MC/DEL MC/DEL MC MC MC/DEL MC/DEL MC MC		AEROBID-M AERS PULMICORT TURBUHALER AEPB ² VANCERIL DOUBLE STRENGTH AERS	1. No PA for Pulmicort susp if under 8 years old 2. No PA for Pulmicort turbobaler if under 14 yr. Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
ANTIASTHMATIC - 5-Lipoxygenase Inhibitors				MC		ZYFLO TABS	Use PA Form # 20420	Other Preferred asthma controller drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
ANTIASTHMATIC - LEUKOTRIENE RECEPTOR ANTAGONISTS	MC/DEL		SINGULAIR ³	MC/DEL		ACCOLATE TABS	1. Must be using inhaled steroid, unless less than 14 years old, for script to avoid requiring a PA. Use PA Form # 20420	Singulair will additionally be approved for allergic indications if other cost effective allergy treatments are ineffective, including oral antihistamines and nasal steroids. Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
ANTIASTHMATIC - ALPHA-PROTEINASE INHIBITOR				MC MC		PROLASTIN SUSR ZEMAIRA	Use PA Form # 20420	Prolastin and Azemaira will be approved for members with A1AT deficiency and clinically demonstrable panacinar emphysema.
ANTIASTHMATIC - HYDRO-LYTIC ENZYMES				MC/DEL		PULMOZYME SOLN	Use PA Form # 20420	Will be approved for cystic fibrosis patients.

			MC	7	PANOKASE TABS	Use PA Form # 20420	
			MC/DEL	8	CREON		
			MC	8	KUTRASE CAPS		
			MC/DEL	8	KU-ZYME CAPS		
			MC/DEL	8	LIPRAM CR		
			MC	8	PANCREASE MT		
			MC/DEL	8	PANCRECARB MS-8 CPEP		
			MC	8	VIOKASE		
GI - ANTI - FLATULENTS / GI STIMULANTS	MC MC/DEL MC/DEL MC MC/DEL MC/DEL MC/DEL MC/DEL	CALULOSE SYRP CONSTULOSE SYRP ENULOSE SYRP GASTROCRUM CONC GENERLAC SYRP LACTULOSE SYRP METOCLOPRAMIDE HCL SIMETHICONE	MC MC MC/DEL MC/DEL		CEPHULAC SYRP GAS-X CHEW INFANTS GAS RELIEF SUSP REGLAN TABS	Diag codes no longer necessary for preferred products. Lactulose has 60cc/day QL Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. As listed in MaineCare Policy, certain drugs require specific diagnoses for approval.
GI - INFLAMMATORY BOWEL AGENTS	MC/DEL MC MC/DEL MC MC MC/DEL MC/DEL MC/DEL	ASACOL TBEC AZULFIDINE TABS AZULFIDINE EN-TABS TBEC CANASA SUPP COLAZAL CAPS DIPENTUM CAPS PENTASA CPCR ROWASA ENEM SULFASALAZINE TABS	MC/DEL		SULFAZINE EC TBEC	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
GI - IRRITABLE BOWEL SYNDROME AGENTS			MC/DEL MC/DEL		LOTROXEX TABS ZELNORM TABS	Use PA Form # 20420	Zelnorm will be approved for women with IBS and predominant constipation. Lotronex will be approved for females with IBS and predominant diarrhea. Prior failed trials of multiple other preferred GI agents must occur first. IBS dx must be thoroughly documented.
MISCELLANEOUS GI							
Preferred drugs that used to require diag codes still require diag codes unless indicated otherwise.							
GI - MISC.	MC/DEL MC/DEL MC MC MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC MC/DEL MC/DEL MC MC/DEL MC/DEL MC MC/DEL MC/DEL MC MC/DEL MC MC/DEL MC/DEL MC MC MC/DEL MC/DEL MC MC MC/DEL MC/DEL MC MC MC/DEL MC/DEL MC MC MC/DEL MC/DEL MC MC MC/DEL MC/DEL	BISAC-EVAC SUPP BISACODYL BISCOLAX SUPP CINOBAC CAPS CITRATE OF MAGNESIA SOLN CITRUCEL D.O.S. CAPS DIOCTO LIOD DIOCTO SYRP DIOCTYN CAPS DOC-Q-LACE CAPS DOCUSATE CALCIUM CAPS DOCUSATE SODIUM DOCUSIL CAPS DOK CAPS FIBER LAXATIVE TABS FLEET GENFIBER POWD GLYCERIN HIPREX TABS KRISTALOSE PACK METAMUCIL MILK OF MAGNESIA SUSP MINERAL OIL OIL MIRALAX PACK ¹ MIRALAX POWD ¹ SENNA SENOKOT GRAN SENOKOT SYRP SENOKOT CHILDRENS SYRP SENOKOT XTRA TABS SORBITOL STOOL SOFTENER CAPS SUCRALFATE TABS UNI-EASE CAPS UNIFIBER POWD URSO FORTE URSODIOL	MC/DEL MC MC/DEL MC/DEL MC MC MC/DEL MC/DEL MC MC/DEL MC MC/DEL MC/DEL MC MC/DEL MC/DEL MC MC/DEL MC/DEL MC MC MC/DEL MC/DEL MC MC MC/DEL MC/DEL MC MC MC/DEL MC/DEL MC MC MC/DEL MC/DEL MC MC MC/DEL MC/DEL		ACTIONIGALL CAPS BENEFIBER CARAFATE COLACE CAPS COLYTE DIOCTO-C SYRP DOC SOD /CAS CAP DOC-Q-LAX CAPS DOCUSATE SODIUM/CAS CAPS DOK PLUS DULCOLAX SUPP FIBER CON TABS FIBER-LAX TABS GOLYTELY SOLR GLYCOLAX ¹ MALTSUPEX NULYTELY SOLR PEG 3350/ELECTROLYTES SOLR SENXON TABS SENOKOT TABS SENOKOT S TABS STOOL SOFTENER PLUS CAPS UNI-CENNA TABS UNI-EASE PLUS CAPS V-R NATURAL SENNA LAXATIV TABS	1. Quantity Limit: 255 g/90-day without PA for greater than 18 years old. No quantity limit for less than 18 years old. 2. Must show evidence of trials of preferred agents that do not require PA, such as OTC senna, docusate, mineral oil and prescription lactulose. Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. As listed in MaineCare Policy, certain drugs require specific diagnoses for approval.
MISC. UROLOGICAL							
UROLOGICAL - MISC.	MC MC/DEL MC MC	ACETIC ACID 0.25% SOLN BICITRA SOLN CYTRA-K SOLN FURADANTIN SUSP	MC MC/DEL MC MC/DEL		CITRIC ACID/SODIUM CITRAT SOLN CYTRA-2 SOLN ELMIRON CAPS ¹ MACROBID CAPS	1. Elmiron requires adequate proof of Dx with supportive testing. Use PA Form #20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.

	MC MC/DEL MC/DEL MC/DEL MC/DEL MC MC MC/DEL MC/DEL MC/DEL MC/DEL MC MC MC/DEL MC MC/DEL		K-PHOS MF TABS MACRODANTIN CAPS METHENAMINE MANDELATE TABS MONUROL PACK NEOSPORIN GU IRRIGANT SOLN PHENAZOPYRIDINE HCL TABS POLYCITRA SYRP POLYCITRA-K SOLN POLYCITRA-LC SOLN PROSED/DS TABS PYRIDUM PLUS TABS RENACIDIN SOLN TRICITRATES SYRP UREX TABS URISED TABS UROCI-K UROID #2 TABS	MC/DEL MC/DEL MC MC MC MC/DEL MC/DEL MC MC MC/DEL MC MC/DEL	MANDELAMINE TABS NITROFURANTOIN MACR CAPS POLYCITRA-K CRYSTALS PACK POTASSIUM CITRATE/CITRIC SOLN PYRIDUM TABS		
PHOSPHATE BINDERS							
PHOSPHATE BINDERS	MC MC/DEL		PHOSLO MEGNEBIND - 400	MC/DEL MC/DEL	FOSRENOL RENAGEL ^{1,2}	1. Renagel will be approved for hypercalcemia, digoxin users, and in cases where maximum phoslo doses are insufficient. 2. Will be verifying patient compliance. Labs must be provided. Please refer to the Phosphate Binders PA form. Use PA Form #20530	Renagel will be approved in patients with hypercalcemia, on concurrent digoxin or insufficient response with Phos-lo (Renagel to be add-on therapy).
INTRA-VAGINALS							
VAGINAL - ANTIBACTERIALS	MC/DEL MC/DEL MC/DEL	1 1 3	CLEOCIN CREA METROGEL VAGINAL GEL CLEOCIN SUPP			Step order must be followed to avoid PA. Must fail Cleocin and Metrogel products before moving to next step product without PA.	Preferred drugs must be tried and failed in step-order due to lack of efficacy or intolerable side effects before less preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
VAGINAL - ANTI FUNGALS	MC/DEL MC/DEL MC MC/DEL MC/DEL MC/DEL MC MC MC MC MC/DEL MC MC		CLOTTRIMAZOLE CREA GYNE-LOTTRIMIN CREA MICONAZOLE CREA MICONAZOLE 3 COMBO PACK KIT ¹ MICONAZOLE 7 CREA MICONAZOLE NITRATE CREA MONISTAT 1 OINT MONISTAT 3 CREA MONISTAT 7 NYSTATIN TABS TERCONAZOLE 0.4MG VAGITROL V-R MICONAZOLE-7 CREA	MC MC MC MC MC/DEL MC MC MC MC MC/DEL	AVC CREAM CLOTTRIMAZOLE 3 DAY CREA GYNAZOLE-1 CREA GYNE-LOTTRIMIN 3 TABS MICONAZOLE 3 SUPP MONISTAT 3 SUPP TERAZOL 3 CREA TERAZOL 3 SUPP TERAZOL 7 CREA TERCONAZOLE 0.8MG	1. Quantity limit: 1/script/2 weeks Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
VAGINAL - CONTRACEPTIVES	MC		GYNOL II EXTRA STRENGTH GEL	MC	DELLEN FOAM	Use PA Form # 20420	Preferred drug must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drug will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
VAGINAL - ESTROGENS	MC/DEL MC/DEL		ESTRING RING PREMARIN CREA	MC/DEL MC/DEL	ESTRACE CREA VAGIFEM TABS	Must fail all preferred products before non-preferred. Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
VAGINAL - OTHER	MC/DEL MC MC		ACID JELLY GEL ACI-JEL GEL CERVICAL AMINO ACID CREA	MC	AMINO ACID CERVICAL CREA	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
BPH							
BPH	MC/DEL MC/DEL MC/DEL MC/DEL		AVODART DOXAZOSIN MESYLATE TABS PROSCAR TABS TERAZOSIN HCL CAPS	MC/DEL MC/DEL MC MC/DEL	5 FLOMAX CP24 8 CARDURA TABS 8 HYTRIN CAPS 8 UROXATRAL	Non-preferred products must be used in specified order. Use PA Form #20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs (in step-order) will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. Approval of a non-preferred 5-alpha reductase inhibitor requires objective clinical evidence of a very enlarged prostate rather than just the presence of obstructive urinary outflow symptoms along with adequate trial of preferred Proscar.
ANXIOLYTICS							
ANXIOLYTICS - BENZODIAZEPINES	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL		ALPRAZOLAM TABS CHLORDIAZEPOXIDE HCL CAPS CLORAZEPATE DIPOTASSIUM TABS DIAZEPAM LORAZEPAM	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL	ATIVAN NIRAVAM SERAX TRANXENE XANAX TABS	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.

	MC/DEL		OXAZEPAM CAPS							
ANXIOLYTICS - LONG ACTING	MC/DEL		XANAX XR ²						1. Xanax XR will be available if the long acting benzo clonazepam fails. Use PA Form # 20420	
ANXIOLYTICS - MISC.	MC/DEL MC MC MC/DEL		BUSPIRONE HCL TABS HYDROXYZINE HCL SOLN HYDROXYZINE HCL SYRP HYDROXYZINE PAMOATE CAPS	MC MC MC MC/DEL MC MC/DEL MC/DEL			ATARAX TABS BUSPAR TABS DROPERIDOL SOLN HYDROXYZINE HCL TABS HYDROXYZINE PAM 100MG CAPS INAPSINE SOLN MEPROBAMATE TABS VISTARIL	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.	
ANTI-DEPRESSANTS										
ANTIDEPRESSANTS - MAO INHIBITORS	MC/DEL MC/DEL		NARDIL TABS PARNATE TABS							
ANTIDEPRESSANTS - SELECTED SSRTs	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC MC/DEL MC/DEL MC/DEL		BUPROPION HCL TABS BUPROPION SR CITALOPRAM ⁶ FLUOXETINE HCL CAPS FLUOXETINE HCL LIQD FLUOXETINE HCL TABS FLUVOXAMINE MALEATE TABS LEXAPRO TABS ⁵ MIRTAZAPINE PAROXETINE ³ PAXIL CR ³ SERZONE TABS TRAZODONE HCL TABS WELLBUTRIN XL ZOLOFT ²	MC MC/DEL MC/DEL MC/DEL MC MC MC MC/DEL MC/DEL MC MC MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL	5 6 6 8 8 8 8 8 8 8 8 8 8 8 8 8 9		CYMBALTA ⁴ EFFEXOR TABS EFFEXOR XR CP24 ³ CELEXA DESYREL TABS FLUOXETINE 40 mg ¹ LUVOX TABS MAPROTILINE HCL TABS PAXIL ¹ PROZAC PROZAC CAPS PROZAC WEEKLY CPDR REMERON TABS SARAFEM CAPS TRAZODONE HCL 300MG TABS WELLBUTRIN TABS WELLBUTRIN SR TBCR REMERON SOLTAB TBDP	Non-preferred products must be used in specified step order. 1. Use Fluoxetine 20 mg in multiples. 2. See Zoloft splitting table. Zoloft requires splitting of 50mg and/or 100mg scored tabs to avoid PA. 3. Strong caution with pediatric population. 4. Established users are grandfathered. 5. See Celebra/Citalopram and Lexapro splitting tables. 6. Max daily dose allowed is 60mg, only 1 per day allowed for all strengths. Use PA Form # 20420	Preferred drugs must be tried for at least 4 weeks each and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. At least one preferred SSRI and one preferred non-SSRI drugs must be tried. Venlafaxine is non-preferred for any anxiety diagnosis and may be approved after trials of one SSRI and one non-SSRI (e.g. any anxiolytic or a tricyclic at any dose). Preferred Fluoxetine will be the only preferred antidepressant for members who are less than 18 years of age. Exceptions to the rule are as follows: 1. If the member (<18) is already an established user for any of the preferred or non-preferred drugs under the Antidepressant category on the PDL, then they can continue to get that drug. 2. If the member (<18) has a prescription for an antidepressant that is on the PREFERRED side of the PDL and has had a 30 day supply of Fluoxetine at least 30 days before the date they are getting it filled, the claim will pay. If they do not have the trial of Fluoxetine in their profile, the claim will reject for PA required. 3. If the member (<18) has a prescription for a medication that is on the NON-PREFERRED side of the PDL regardless of having Fluoxetine in their profile, the prescription will need a PA. 4. Use of a preferred antidepressant for anxiety will require pa to establish anxiety diagnosis. 5. Use of bupropion or Wellbutrin for ADHD diagnosis must show prior trial/failure with methylphenidate and amphetamine <u>Special Kid < 18yo Criteria for New Starters:</u> Must have had fluoxetine trial for at least 30 days before accessing other preferred antidepressants without PA. Cymbalta - Second line therapy for Diabetic Peripheral Neuropathy and Post Herpetic Neuralgia after trial of a preferred TCA (tri-cyclic anti-depressant) and one of the following preferred medications: a preferred anti-convulsant, capsaicin, tramadol, or other narcotic. Combination therapy of non-preferred medications for Diabetic Peripheral Neuropathy and Post Herpetic Neuralgia will not be approved.	
ANTIDEPRESSANTS - TRI-CYCLICS	MC/DEL MC MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC MC/DEL MC		AMITRIPTYLINE HCL TABS AVENTYL SOLN CLOMIPRAMINE HCL CAPS DESIPRAMINE HCL TABS DOXEPIN HCL IMIPRAMINE HCL TABS NORTRIPTYLINE HCL PROTRIPTYLINE HCL TABS SURMONTIL CAPS	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC MC/DEL MC MC			AMOXAPINE TABS ANAFRANIL CAPS ELAVIL TABS NORPRAMIN TABS PAMELOR SINEQUAN TOFRANIL VIVACTIL TABS	PA required for new starters if over 65 years old. Users over 65 years old are grandfathered. Use PA Form # 20420 or 102220	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.	
SEDATIVE / HYPNOTICS										
SEDATIVE/HYPNOTICS - BARBITURATE	MC MC/DEL MC MC/DEL		BUTISOL SODIUM TABS CHLORAL HYDRATE SYRP MEBARAL TABS PHENOBARBITAL	MC MC MC/DEL			LUMINAL SOLN SECONAL CAPS SOMNNOTE CAPS	PA required for new users of preferred products if over 65 years old. Use PA Form # 30110	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.	
SEDATIVE/HYPNOTICS - BENZODIAZEPINES	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL		DORAL TABS ESTAZOLAM TABS FLURAZEPAM HCL CAPS TEMAZEPAM CAPS TRIAZOLAM TABS	MC MC MC MC MC/DEL			DALMANE HALCION TABS MIDAZOLAM HCL SYRP PROSOM TABS RESTORIL CAPS	Previous quantity limits still apply. Use PA Form # 30110	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. Benzodiazepines do cause dependence with continued use and usage should be limited to 7-10 days at a time. Chronic intermittent use (2-3 Days per week max) is the standard of care	
SEDATIVE/HYPNOTICS - Non-Benzodiazepines	MC/DEL MC/DEL MC		LUNESTA ¹ MIRTAZAPINE TRAZODONE	MC/DEL MC/DEL MC/DEL	7 8 8 9		AMBIEN SONATA CAPS ROZEREM AMBIEN CR	Must fail all preferred products before non-preferred. 1. Quantity Limit of 12 per 34 days. Use PA Form # 30110	Preferred drug must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. Ambien and Sonata do cause dependence with continued use and as with benzodiazepines, usage should be limited to 7-10 days at a time. Chronic intermittent use (2-3 days per week max) is the standard of care. Please see Sedative/Hypnotic PA form.	
ANTI-PSYCHOTICS										
ANTIPSYCHOTICS - ATYPICALS	MC MC/DEL MC/DEL MC/DEL MC		RISPERDAL GEODON SEROQUEL TABS ABILIFY TABS ZYPREXA TABS	MC MC MC MC MC	8 8		RISPERDAL CONSA RISPERDAL M TAB	1. If prescribing 2 or more antipsychotics, PA will be required for both drugs, except if one is Clozapine. See Multiple Antipsychotic PA form #20440	Preferred drugs subject to step order must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. Atypicals will be approved, subject to step-order, for patients with FDA-approved indications and for specific conditions supported by at least two published peer-reviewed double-blinded, placebo-controlled randomized trials that are not contradicted by other studies of similar quality and as long as all first line preferred therapies have been tried and failed at full therapeutic doses for adequate durations (at least two weeks). * Abilify: doses above 15mg were not shown to be more effective than doses in the 10-15mg range .4. Seroquel 25mg is available without PA if the following conditions are met: a.) Either 65 years of age or older or less than 18 years of	

	MC	ZYPREXA ZYDIS TBDP				2. All atypicals have dosing limitations and maximum daily doses. Please refer to dose consolidation table for any potential dosing limits. Maximum daily doses are as follows: Abilify- 30mg daily max Risperdal- 8mg daily max Seroquel- 800mg daily max Zyprexa- 30mg daily max Use PA form #10420 for requests exceeding these maximum daily doses.		age, b.) dosage is for 3 or more per day, c.) Seroquel 25mg is in the profile within the last 45 days.
ANTIPSYCHOTICS - SPECIAL ATYPICALS	MC/DEL	CLOZAPINE TABS	MC/DEL MC		CLOZARIL TABS FAZACLO	Use PA Form # 20420		Preferred generic drug must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred brand will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. Patients previously stabilized on brand name drug will be approved.
ANTIPSYCHOTICS - TYPICAL	MC/DEL MC/DEL MC MC/DEL MC MC MC/DEL MC/DEL MC MC/DEL MC/DEL MC MC/DEL MC/DEL MC MC/DEL MC MC/DEL	CHLORPROMAZINE HCL FLUPHENAZINE DECANOATE FLUPHENAZINE HCL HALDOL HALOPERIDOL HALOPERIDOL DECANOATE SOLN HALOPERIDOL LACTATE SOLN LOXAPINE SUCCINATE CAPS LOXITANE-C CONC MOBAN TABS PERPHENAZINE PROCHLORPERAZINE SERENTIL THIORIDAZINE HCL THIOTHIXENE THORAZINE SUPP TRIFLUOPERAZINE HCL TABS	MC/DEL MC/DEL MC MC/DEL MC MC/DEL MC MC MC MC MC/DEL MC/DEL MC MC/DEL MC MC/DEL MC MC/DEL		COMPAZINE COMPRO SUPP HALDOL DECANOATE LOXITANE CAPS MELLARIL NAVANE CAPS PROLIXIN STELAZINE TABS THORAZINE	Use PA Form # 120420		Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
LITHIUM								
LITHIUM	MC/DEL MC/DEL MC/DEL MC/DEL	ESKALITH CAPS ESKALITH CR TBCR LITHIUM CARBONATE LITHIUM CITRATE SYRP						
COMBINATION - PSYCHOTHERAPEUTIC								
PSYCHOTHERAPEUTIC COMBINATION	MC/DEL MC/DEL	CHLORDIAZEPOXIDE/AMITRIPT PERPHENAZINE/AMITRIPTYLIN	MC	8	SYMBYAX	Use PA Form # 20420		Use individual components, which are currently available without a PA.
STIMULANTS								
STIMULANT - AMPHETAMINES SHORT ACTING	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL	ADDERALL TABS AMPHETAMINE SALT COMBO DEXEDRINE DEXTROAMPHET SULF TABS DEXTROSTAT TABS						Preferred stimulants will be available without PA if diagnosis of ADHD As per recent FDA alert, Adderall should not be used in patients with underlying heart defects since they may be at increased risk for sudden death.
STIMULANT - LONG ACTING AMPHETAMINES SALT	MC/DEL	ADDERALL XR CP24						Preferred stimulants will be available without PA if diagnosis of ADHD As per recent FDA alert, Adderall should not be used in patients with underlying heart defects since they may be at increased risk for sudden death.
LONG ACTING AMPHETAMINES	MC MC	DEXEDRINE CAP CR DEXTROAMPHET SULF CPCR						
STIMULANT - METHYLPHENIDATE	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL	FOCALIN TABS METADATE ER TBCR METHYLIN ER TBCR METHYLIN TABS METHYLIN SOL	MC MC/DEL		METHYLIN CHEWABLES RITALIN	Use PA Form # 20420		Preferred stimulants will be available without PA if diagnosis of ADHD. Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. Please refer to General Criteria category E.

	MC/DEL		METHYLPHENIDATE HCL								
STIMULANT - METHYLPHENIDATE - LONG ACTING	MC MC		CONCERTA TBCR FOCALIN XR	MC MC/DEL	5 8	METADATE CD CPCR ¹ RITALIN LA	Preferred stimulants will be available without PA if diagnosis of ADHD. Non-preferred products must be used in specified step order. 1. Easily approved for patients needing the sprinkles. Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.			
STIMULANT - STIMULANT LIKE				MC MC MC/DEL MC MC	7 8 8 9 9	STRATTERA ^{1,2} CAFCIT SOLN PROVIGIL TABS DESOXYN TABS DESOXYN CR	1. Failure of both an amphetamine and methylphenidate is required for consideration for approval of Strattera, unless history of substance abuse without current use of abusable medication(s) 2. Strattera currently has dosing limitations allowing one tablet per day for all strengths if obtain approval. Please refer to PDL dosage consolidation chart. 3. Non-preferred products must be used in specified step order. Provigil: use PA Form # 20710; Others: use Pa Form # 20420	Provigil requests require diagnosis of Narcolepsy, ADHD, or Obstructive Sleep Apnea. Previous failures of methylphenidate and amphetamine is required for Narcolepsy and ADHD diagnosis, with additional Strattera trial needed with ADHD diagnosis. Please refer to detailed criteria on Provigil PA form			
ANTI-CATAPLECTIC AGENTS											
PSYCHOTHERAPEUTIC AGENTS MISC.				MC/DEL		XYREM SOL	Use PA Form #20710				
WEIGHT LOSS											
WEIGHT LOSS							No longer covered.	Weight loss drugs are not covered as permitted by Federal Medicaid regulations and Maine Medicaid (MaineCare) Policy.			
ALZHEIMER DISEASE											
ALZHEIMER - Cholinomimetics/Others	MC MC/DEL MC/DEL		ARICEPT TABS ¹ EXELON ¹ NAMENDA ¹	MC MC MC	8 8 9	RAZADYNE REMINYL COGNEX CAPS	1. All new users need PA to establish dementia diagnosis and baseline mental status score. Must fail all preferred products before moving to non-preferred. Use PA Form #20420	Preferred drug must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs (in step-order) will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.			
SMOKING CESSATION											
NICOTINE PATCHES / TABLETS	MC/DEL		NICODERM CO PT24				Bupropion SR 150 mg is available without a prior authorization.	OTC Nicotine products are covered by MaineCare Policy when they have been determined to be cost-effective. Only Nicoderm and the generic nicotine gums have received this designation as preferred. All other nicotine products (OTC & prescription) are non-preferred by MaineCare Policy. Preferred drug must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs (in step-order) will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. Another version of Zyban, Bupropion SR (100 and 150mg) is available without PA. There will be a quantity limit of 3 months supply of nicotine products allowed per 12 months.			
NICOTINE REPLACEMENT - OTHER	MC/DEL MC/DEL		NICOTINE POLACRILEX GUM NICORETTE GUM	MC/DEL MC/DEL MC/DEL	5	COMMIT LOZENGES ¹ NICOTROL INHALER NICOTROL NASAL SPRAY	Must fail all preferred products from smoking cessation category (Nicoderm patch and nicotine gum) before moving to non-preferred. Must use Non-preferred products in specified step order. 1. Will be available to patients unable to tolerate preferred products. Use PA Form # 20420	OTC Nicotine products are covered by MaineCare Policy when they have been determined to be cost-effective. Only Nicoderm and the generic nicotine gums have received this designation as preferred. All other nicotine products (OTC & prescription) are non-preferred by MaineCare Policy. Both preferred Nicotine gum and Nicoderm patch must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs (in step-order) will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. There will be a quantity limit of 3 months supply of nicotine products allowed per 12 months.			
ALCOHOL DETERRENTS											
ALCOHOL DETERRENTS	MC MC MC/DEL MC		DISULFIRAM TABS ANTABUSE TABS NALTREXONE HCL TABS CAMPRAL ¹				1. Should only be used in conjunction with formal structured outpatient detoxification program.	Preferred generic drug must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.			
MISCELLANEOUS ANALGESICS											
ANALGESICS - MISC.	MC MC/DEL		ACEPHEN SUPP ACETAMIN TAB 325MG	MC MC		ASPIR-81 TBEC AXOCET CAPS	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.			

MC/DEL	ACETAMINOPHEN	MC	DOLOBID TABS		
MC/DEL	ASPIRIN	MC	EASPRIN TBEC		
MC/DEL	ASPIRIN EC	MC	EQUAGESIC TABS		
MC/DEL	ASPIR-LOW TBEC	MC/DEL	ESGIC-PLUS		
MC/DEL	BUFFERED ASPIRIN TABS	MC	EXCEDRIN TAB ASA FRE		
MC/DEL	BUTAL/ASA/CAFF	MC/DEL	FIORICET TABS		
MC/DEL	BUTALBITAL COMPOUND	MC	FIORINAL CAPS		
MC/DEL	BUTALBITAL/ACET TABS	MC	FIORTAL CAPS		
MC/DEL	BUTALBITAL/APAP CAPS	MC/DEL	FORTABS TABS		
MC/DEL	BUTALBITAL/APAP/CAFFEINE	MC	PHRENILIN TABS		
MC/DEL	CHILDRENS ASPIRIN CHEW	MC	PHRENILIN FORTE CAPS		
MC/DEL	CHILDRENS PAIN RELIEVER	MC	TRILISATE LIQD		
MC/DEL	CHOLINE MAGNESIUM TRISALI	MC	TRILISATE TABS		
MC/DEL	DIFLUNISAL TABS	MC	ZEBUTAL CAPS		
MC/DEL	ECOTRIN	MC	ZORPRIN TBCR		
MC/DEL	FEVERALL SUPP				
MC/DEL	GENAPAP				
MC/DEL	GENEBS TABS				
MC	HEADACHE FORMULA ADDED TABS				
MC	INFANTAIRE SOLN				
MC	INFANTS APAP SOLN				
MC	INFANTS PAIN RELIEVER SUSP				
MC/DEL	MAPAP				
MC/DEL	PAIN RELIEVER				
MC/DEL	Q-NOL TABS				
MC/DEL	SALSALATE TABS				
MC	TACTINAL EXTRA STRENGTH TABS				
MC	TYLENOL				
MC	V-R CHILDRENS ASPIRIN CHEW				
MC	V-R NON-ASPIRIN TABS				

LONG ACTING NARCOTICS

NARCOTICS - LONG ACTING	MC	AVINZA	MC	7	DURAGESIC PT72 ²	Non-preferred products must be used in specific order. 1. Duragesic will be available without PA for patients treated for or dying from cancer or hospice patients. CA (cancer) or HO (hospice) diag code may be used but store must verify since all scripts will be audited and stores will be liable. 2. Established users are grandfathered. 3. Oxycodone ER allowed only per day for all strengths except 80 mg, where 4 are	Preferred drugs (Avinza or morphine sulfate ER tab, Methadone or Melhadose, & oxycodone ER) & step order drugs must be tried for at least 2 weeks each & failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug & the preferred drug(s) exists. Adequate trials include prevention/treatment of common adverse effects associated w/ narcotics (anti-nausea, antipruritics, etc.) as well as adequate equianalgesic dosing when converting from one narcotic to another. Also, adequate documentation of attempts to titrate dose of preferred agents to achieve adequate pain relief & desired clinical response must be provided. Member's drug regimen for additions &/or discontinuations of medications that may affect absorption &/or metabolism of preferred agents must be monitored. Approvals will not be granted if patient had access to either non-preferred products or high doses of short acting narcotics during the trial period. Non-preferred drugs will not be approved for patients showing evidence of substance abuse such as: 1. Frequent or persistent early refills of controlled drugs; 2. Multiple instances of early refill overrides due to reports of misplacement, stolen, dropped in toilet or sink, distant travel, etc.; 3. Breaches of narcotic contracts with any provider; 4. Failure to comply with patient responsibilities in attached opioid documentation (see PA form) including but not limited to failing to submit to and pass pill counts; 5. Failing to take or pass random drug testing; 6. Failing to provide old records regarding prior use of narcotics; 7. Receiving controlled substances from other prescribers that the provider submitting the PA is unaware of 8. Documented history of substance abuse. Substance abuse evaluations may be required for patients with medical records displaying documented substance abuse or potential signs of narcotic misuse and abuse such as chronic early refills, short dosing intervals, frequent dose increases, multiple lost/stolen etc. scripts and intolerance or "allergy" to all products but Oxycotin. 9. Circumventing MaineCare prior authorization
	MC/DEL	METHADONE	MC/DEL	8	ORAMORPH SR TB12		
	MC/DEL	METHADOSE	MC/DEL	8	MORPHINE SULFATE SUPP		
	MC/DEL	MORPHINE SULFATE ER TB12 ²	MC/DEL	8	MS CONTIN TB12		
	MC/DEL	OXYCODONE ER ^{3,4}	MC	8	KADIAN CP 24 ²		
			MC/DEL	9	OXYCONTIN TB12 ²		

TREATMENTS

max dosing limits of 32mg daily if the following conditions are met: a.) There is not another Suboxone script in member's drug profile within the past 30 days. and b.) There is not more than one narcotic fill in member's drug profile between today's fill of suboxone and a prior suboxone fill within the past 90 days.

on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. Subtext will only be approved for use during pregnancy.

	MC/DEL	2	PERGOLIDE MESYLATE TABS			USE PA Form # 20420	another drug and the preferred drug(s) exists.
PARKINSONS - DOPAMINERGICS/CARBII/ LEVO	MC/DEL		AMANTADINE HCL	MC/DEL		APOKYN* ELDEPRYL CAPS PARLODEL CAPS PARLODEL TABS SINEMET TABS SINEMET TBCR SYMMETREL TABS	* Only preferred manufacturer's products will be available without prior authorization. Use PA Form # 20420 Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
	MC/DEL		BROMOCRIPTINE MESYLATE	MC			
	MC/DEL		CARBIDOPA/LEVODOPA TABS*	MC/DEL			
	MC/DEL		CARBIDOPA/LEVODOPA ER	MC/DEL			
	MC		LARODOPA TABS	MC			
	MC		LODOSYN TABS	MC			
	MC/DEL		SELEGILINE HCL	MC			
PARKINSONS - COMBO.	MC/DEL		STALEVO				
MUSCLE RELAXANTS							
ALS DRUG	MC/DEL		RILUTEK TABS				
MUSCLE RELAXANTS	MC/DEL		BACLOFEN TABS	MC/DEL	7	ORPHENADRINE CITRATE	Non-preferred drugs will not be approved if members circumventing MaineCare prior authorization requirements by paying (prescribers failed to submit prior authorization prior to cash narcotic scripts being filled by member). Non-preferred products must be used in specified step order. Both step 7's must be tried. Use PA Form # 20420
	MC/DEL		CHLORZOXAZONE TABS	MC/DEL	7	TIZANIDINE HCL TABS	
	MC/DEL		CYCLOBENZAPRINE HCL TABS	MC/DEL	8	CARISOPRODOL TABS ¹	
	MC		LIORESAL INTRATHECAL KIT	MC/DEL	8	DANTRIUM CAPS	
	MC/DEL		METHOCARBAMOL TABS	MC/DEL	8	FLEXERIL TABS	
				MC	8	LIORESAL TABS	
				MC	8	NORFLEX TBCR	
				MC	8	ROBAXIN-750 TABS	
				MC/DEL	8	ZANAFLEX TABS	
				MC/DEL	9	SKELAXIN TABS	
				MC/DEL	9	SOMA TABS	
MUSCLE RELAXANT - COMBO.				MC/DEL		CARISOPRODOL/ASPIRIN TABS	Use PA Form # 20420 Individual components are available with PA described in the section above.1. frequent or persistent early refills of non-controlled drugs; 2. multiple instances of early refill overrides due to reports of misplacement stolen, dropped in toilet or sink, distant travel, etc.
				MC/DEL		CARISOPRODOL/ASPIRIN/CODE	
				MC		NORGESIC TABS	
				MC/DEL		ORPHENADRINE COMPOUND	
				MC/DEL		ORPHENADRINE/ASA/CAFF	
				MC		ORPHENGESIC	
VITAMINS							
Preferred products that used to require diag codes still require diag codes unless indicated otherwise.							
VITAMINS	MC/DEL		ASCORBIC ACID TABS	MC		AQUASOL E SOLN	Use PA Form # 20420 Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. As listed in MaineCare Policy, certain drugs require specific diagnoses for approval.
	MC		BIOTIN	MC		AQUAVIT-E SOLN	
	MC		CYANOCOBALAMIN SOLN	MC		DHT SOLN	
	MC		FOLGARD RX 2.2 TABS	MC		NASCOBAL GEL	
	MC/DEL		FOLIC ACID TABS				
	MC		FOLTX TABS				
	MC/DEL		MEPHYTON TABS				
	MC/DEL		NIACIN				
	MC		NIACOR TABS				
	MC/DEL		NICOTINIC ACID SR CPCR				
	MC		PYRIDOXINE HCL TABS				
	MC/DEL		SLO-NIACIN TBCR				
	MC/DEL		THIAMINE HCL SOLN				
	MC/DEL		VITAMIN B-1 TABS				
	MC/DEL		VITAMIN B-12				
	MC		VITAMIN B-6 TABS				
	MC/DEL		VITAMIN C				
	MC/DEL		VITAMIN E CAPS				
	MC/DEL		VITAMIN E/D-ALPHA CAPS				
	MC		VITAMIN K1 SOLN				
	MC		V-R VITAMIN E CAPS				
VITAMIN D's	MC		CALCIFEROL SOLN ¹	MC/DEL		DRISDOL CAPS	1. Diagnosis of dialysis (renal failure) required. 2. OTC Vitamin D no diagnosis required. Preferred products require dialysis/renal failure diagnosis. Non-preferred products require: Secondary hyperparathyroidism in patients with Chronic Kidney Disease on dialysis., iPTH<400 pg/ml, Phosphorous <6.5mg/dl, corrected calcium <12.2mg/dl, corrected calcium x phosphorous products <70mg ² /dl ²
	MC/DEL		CALCITRIOL CAPS ¹	MC		CALCIJEX	
	MC/DEL		DRISDOL SOLN ¹	MC/DEL		HECTOROL (ORAL)	
	MC/DEL		VITAMIN D ^{1,2}	MC/DEL		HECTOROL (PARENTERAL)	
				MC		ROCALTROL ZEMPLAR	

MISC MULTI-VITAMINS

****Preferred products that used to require diag codes still require diag codes unless indicated otherwise.****

VITAMINS - MISC.							
MC	CENTRUM LIQD	MC	ADEKS	Diag codes are no longer required on prenatal vitamins.	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. As listed in MaineCare Policy, certain drugs require specific diagnoses for approval.	
MC/DEL	CENTRUM TABS	MC/DEL	ADVANCED NATALCARE TABS				
MC	CENTRUM JR/IRON CHEW	MC	CENTRUM JR/EXTRA C CHEW				
MC	CENTRUM SILVER TABS	MC	CENTRUM PERFORMANCE TABS				
MC	CENTRUM-LUTEIN TABS	MC	DALYVITE LIQD				
MC	CEROVITE ADVANCED FO TABS	MC	EMBREX 600 MISC				
MC/DEL	CHEWABLE MULTIVIT/FL CHEW	MC	IBERET				
MC	COD LIVER OIL CAPS	MC	MATERNA TABS				
MC	COMPLETE SENIOR TABS	MC	MULTIRET FOLIC-500 TBCR				
MC	DAILY MULTI VIT/IRON	MC/DEL	NATAFORT TABS				
MC/DEL	DIALYVITE 800MG	MC/DEL	NATALCARE CFE 60 TABS				
MC/DEL	FULL SPECTRUM B	MC/DEL	NATALCARE GLOSS TABS				
MC	M.V.I.-12 INJ	MC	NATALCARE PIC TABS				
MC	MULTI-VIT/FLUORIDE	MC	NATALCARE PIC FORTE TABS				
MC/DEL	NATACHEW CHEW	MC/DEL	NATALCARE PLUS TABS				
MC/DEL	NATALCARE RX TABS	MC	NATALCARE THREE TABS				
MC/DEL	O-CAL PRENATAL	MC	NATALFIRST TABS				
MC/DEL	OCUVITE TABS	MC	NATATAB RX TABS				
MC/DEL	ONE DAILY TABS	MC/DEL	NEPHPLEX RX TABS				
MC/DEL	ONE-DAILY MULTIVITAMINS	MC/DEL	NEPHROCAPS CAPS				
MC/DEL	ONE-TABLET-DAILY	MC/DEL	NEPHRO-VITE TABS				
MC/DEL	POLY-VIT/IRON/FLUORID SOLN	MC	NESTABS RX TABS				
MC/DEL	POLY-VITAMIN/FLUORIDE SOLN	MC/DEL	NIFEREX				
MC/DEL	POLY-VITAMINS/IRON SOLN	MC/DEL	NUTRINATE CHEW				
MC/DEL	PRENATAL TABS	MC	POLY-VI-FLOR SOLN				
MC/DEL	PRENATAL FORMULA 3 TABS	MC	POLY-VI-SOL SOLN				
MC/DEL	PRENATAL PLUS TABS	MC	POLY-VI-SOL/IRON SOLN				
MC/DEL	PRENATAL PLUS NF TABS	MC	POLY-VITAMIN DROPS SOLN				
MC	PRENATAL PLUS/27MG IRON	MC	PRECARE				
MC	PRENATAL PLUS/IRON TABS	MC	PREMESIS RX TABS				
MC/DEL	PRENATAL RX/BETA-CAROTENE	MC	PRENATABS CBF TABS				
MC	PROTEGRA CAPS	MC	PRENATAL 19 CHEW				
MC	STRESS TAB NF TABS	MC	PRENATAL CARE TABS				
MC	THERAPEUTIC-M TABS	MC	PRENATAL MR 90 TBCR				
MC	THERAVITE LIQD	MC/DEL	PRENATAL MTR/SELENIUM TABS				
MC/DEL	TRI-VITAMIN/FLUORIDE SOLN	MC	PRENATAL OPTIMA ADVANCE TABS				
MC	VITA CON FORTE CAPS	MC	PRENATAL PC 40 TABS				
MC	VITAMIN B COMPLEX CAPS	MC/DEL	PRENATAL RX TABS				
MC	VITAPLEX PLUS TABS	MC	PRENATE				
		MC	PRIMACARE MISC				
		MC/DEL	RENAL CAPS				
		MC/DEL	RENAPHRO CAPS				
		MC/DEL	RENA-VITE RX TABS				
		MC	STUARTNATAL PLUS 3 TABS				
		MC	TRI-VI-SOL SOLN				
		MC	TRI-VI-SOL/IRON SOLN				
		MC/DEL	ULTRA NATALCARE TABS				
		MC	ULTRA-NATAL TABS				
		MC	VICON FORTE CAPS				
		MC	VINATAL FORTE TABS				
		MC	VINATE				
		MC/DEL	VINATE ADVANCED TABS				

MISCELLANEOUS MINERALS

****Preferred products that used to require diag codes still require diag codes unless indicated otherwise.****

MINERALS							
MC	CALCARB	MC	ANEMAGEN	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. As listed in MaineCare Policy, certain drugs require specific diagnoses for approval.		
MC	CALCI-MIX CAPSULE CAPS	MC	CALCET TABS				
MC	CALCIQUID SYRP	MC/DEL	CALCIUM 600-D TABS				
MC	CALCITRATE/VITAMIN D TABS	MC	CALCIUM/VITAMIN D TABS				
MC/DEL	CALCIUM	MC	CALTRATE 600 PLUS/VIT D TABS				
MC/DEL	CALCIUM CARBONATE	MC	CALTRATE PLUS TABS				
MC/DEL	CALCIUM CITRATE TABS	MC	CHROMAGEN				
MC/DEL	CALCIUM GLUCONATE TABS	MC	CITRACAL PLUS TABS				
MC/DEL	CALCIUM LACTATE TABS	MC	CONTRIN CAPS				
MC	CALCIUM/MAGNESIUM TABS	MC	FEOGEN FORTE CAPS				
MC/DEL	CALCIUM/VITAMIN D TABS	MC	FEROCON CAPS				
MC	CALTRATE 600 TABS	MC/DEL	FERREX 150 CAPS				
MC/DEL	CHEWABLE CALCIUM CHEW	MC	FERRO-SEQUELS TBCR				
MC	CITRACAL TABS	MC	FE-TINIC CAPS				
MC	CITRACAL + D TABS	MC	FE-TINIC 150 FORTE CAPS				

MC	CITRUS CALCIUM TABS	MC/DEL	FLUOR-A-DAY SOLN
MC	CITRUS CALCIUM 1500 + D TABS	MC/DEL	K-DUR TBCR
MC	MC/DEL	MC	KLOR-CON PACK
MC	EFFERVESCENT POTASSIUM TBEP	MC	K-LYTE
MC/DEL	FEOSTAT CHEW	MC/DEL	K-PHOS TABS
MC	FERATAB TABS	MC	K-TABS TBCR
MC/DEL	FER-GEN-SOL SOLN	MC	K-VESCENT PACK
MC/DEL	FERGON TABS	MC	NU-IRON 150 CAPS
MC	FER-IN-SOL SOLN	MC/DEL	OYSTER SHELL CALCIUM/VITA TABS
MC	FER-IRON SOLN	MC/DEL	POLY-IRON 150 CAPS
MC	FERRONATE TABS	MC/DEL	POLYSACCHARIDE IRON CAPS
MC	FERROUS FUMARATE TABS	MC/DEL	POTASSIUM BICARB/CHLORIDE
MC/DEL	FERROUS GLUCONATE TABS	MC/DEL	SLOW FE TBCR
MC/DEL	FERROUS SULFATE	MC	TUMS 500 CHEW
MC/DEL	FLUOR-A-DAY CHEW	MC	VIACTIV CHEW
MC	FLUORIDE CHEW		
MC	FLUORIDE SODIUM CHEW		
MC	FLUORITAB CHEW		
MC	HEMOCYTE TABS		
MC	HM CALCIUM TABS		
MC	K+ POTASSIUM PACK		
MC	KAON ELIX		
MC	KAON-CL-10 TBCR		
MC	KCL 0.075%/DSW/NACL 0.2% SOLN		
MC	K-EFFERVESCENT TBEP		
MC	KLOR-CON		
MC	KLOTRIX TBCR		
MC/DEL	K-PHOS TABS		
MC/DEL	K-VESCENT TBEP		
MC/DEL	LURIDE CHEW		
MC/DEL	MAGNESIUM GLUCONATE TABS		
MC/DEL	MAGNESIUM SULFATE SOLN		
MC	MAGTABS		
MC	MICRO-K CPCR		
MC/DEL	NEUTRA-PHOS		
MC/DEL	OS-CAL TABS		
MC/DEL	OS-CAL 500 + D TABS		
MC/DEL	OYSCO		
MC/DEL	OYST-CAL TABS		
MC/DEL	OYST-CAL D TABS		
MC/DEL	OYST-CAL/VITAMIN D TABS		
MC/DEL	OYSTER CALCIUM TABS		
MC/DEL	OYSTER SHELL		
MC	PHARMA FLUR		
MC/DEL	PHOSPHA 250 NEUTRAL TABS		
MC	POTASSIUM BICARBONATE TBEP		
MC/DEL	POTASSIUM CHLORIDE		
MC	POTASSIUM EFFERVESCENT		
MC/DEL	SELENIUM TABS		
MC	SLOW-MAG TBCR		
MC/DEL	SODIUM FLUORIDE		
MC/DEL	SSKI SOLN		
MC	V-R CALCIUM		
MC	V-R OYSTER SHELL CALCIUM		
MC	ZINC SULFATE CAPS		

MISC. ELECTROLYTES/NUTRITIONALS

ELECTROLYTES/ NUTRITIONALS	MC/DEL	FISH OIL CAPS	MC	BOOST	This list of nutritionals is incomplete. All nutritionals still require a PA except for the miscellaneous products listed as preferred. SGA form required for nutritionals unless member has a G/I tube.	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. As listed in MaineCare Policy, certain drugs require specific diagnoses for approval.
	MC	INTRALIPID EMUL	MC	CASEC POWD		
	MC	MCT OIL OIL	MC	CHOICE DM LIQD		
	MC	ORALYTE SOLN	MC	DELIVER 2.0 LIQD		
	MC	P.T.E. - 5 SOLN	MC	ENFAMIL		
	MC	PEDIALYTE SOLN	MC	ENSURE		
			MC	GLUCERNA		
			MC	ISOCAL LIQD		
			MC	KINDERCAL TF LIQD		
			MC	KINDERCAL TF/FIBER LIQD		
			MC/DEL	L-CARNITINE CAPS		
			MC	LIPISORB LIQD		
			MC	MODULEN IBD POWD		
			MC	NUTRAMIGEN POWD		
				Use PA Form # 20420 & SGA Form		

				MC/DEL		NUTREN			
				MC		NUTRITIONAL SUPPLEMENT LIQD			
				MC		NUTRIVENT 1.5 LIQD			
				MC		OMACOR			
				MC/DEL		PEPTAMEN			
				MC		PHENYL-FREE			
				MC		PKU 3 POWD			
				MC		PREGESTIMIL POWD			
				MC/DEL		PROBALANCE LIQD			
				MC		PROSOBEE			
				MC		SCANDISHAKE PACK			
ERYTHROPOIETINS									
ERYTHROPOIETINS				MC	5	PROCRIPT SOLN ¹	1. All products require PA	Non-Preferred drugs must be tried and failed in step-order, due to lack of efficacy or intolerable side effects before non-preferred drugs will be	
				MC	6	EPOGEN SOLN	but Procrit is first choice. Still	approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents	
				MC	8	ARANESP SOLN	must be used in specified	usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. Please see the	
							step order. Use PA Form #	EPO PA form for other approval and renewal criteria.	
							10520		
GRANULOCYTE CSF									
GRANULOCYTE CSF				MC	8	LEUKINE	Must be used in specified	See approval criteria detailed on Neupogen PA form.	
				MC	8	NEUPOGEN SOLN ¹	step order. 1. 10 day		
				MC	9	NEULASTA	supply/month may be used		
							without a PA. Use PA Form #		
							20520		
ANTICOAGULANTS / PLATELET AGENTS									
ANTICOAGULANTS	MC		ARIXTRA SOLN	MC		COUMADIN TABS	1. Fragmin and Lovenox	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered	
	MC/DEL		FRAGMIN INJ ¹	MC		IPRIVAS C	therapy durations greater	on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the	
	MC		HEPARIN SODIUM/NACL 0.9% SOLN				than 7 days require PA.	preferred drug(s) exists. Exceeding days supply limits for LMWH class requires PA.	
	MC		HEP-LOCK SOLN				Use PA Form # 20420		
	MC/DEL		INNOHEP						
	MC/DEL		LOVENOX SOLN ¹						
	MC/DEL		WARFARIN SODIUM TABS						
	MC		HEPARIN LOCK SOLN						
	MC/DEL		HEPARIN LOCK FLUSH SOLN						
	MC/DEL		HEPARIN SODIUM SOLN						
	MC/DEL		HEPARIN SODIUM LOCK FLUSH SOLN						
	MC/DEL		JANTOVEN						
ANTIHEMOPHILIC AGENTS	MC		ALPHANATE	MC		ADVATE ^{1,2}	1. Only if other products	Non-preferred will only be approved if other preferred products are unavailable.	
	MC/DEL		BENEFIX SOLR				unavailable.		
	MC		BIOCLATE				2. Advate may be available		
	MC/DEL		HELIXATE FS KIT				with PA in cases of large		
	MC		HEMOFIL - M				volume dosing in patients with		
	MC		HUMATE-P SOLR				poor venous access.		
	MC		KOGENATE FS				Use PA Form # 20420		
	MC		KONYNE - 80						
	MC		MONARC - M						
	MC		MONOCLATE - P						
	MC		MONONINE						
	MC/DEL		NOVOSEVEN SOLR						
	MC		PROPLEX - T						
	MC		RECOMBINATE SOLR						
	MC		REFACTO						
PLATELET AGGREGATION INHIBITORS	MC/DEL		ASPIRIN	MC/DEL	7	TICLOPIDINE HCL TABS	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered	
	MC/DEL		DIPYRIDAMOLE TABS	MC/DEL	8	PERSANTINE TABS	1. As of 04.01.2005 Plavix is	on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the	
	MC/DEL		PLAVIX TABS ¹	MC	8	TICLID TABS	only available without PA if	preferred drug(s) exists.	
							concurrent aspirin use (on		
							prescription) within 100 days		
							or documented failure or		
							intolerance or other		
							contraindication to aspirin.		
PLATELET AGGR. INHIBITORS COMBO'S - MISC.	MC/DEL		PENTOXIFYLLINE ER TBCR	MC/DEL		AGGRENOX CPT ^{1,2}	1. Aspirin and dipyridamole	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered	
	MC/DEL		CILOSTAZOL	MC/DEL		AGRYLIN CAPS	are available separately	on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the	
				MC/DEL		PLETAL TABS	without PA. Use PA Form #	preferred drug(s) exists.	
				MC		TRENTAL TBCR	20420		
HEMOSTATIC									
HEMOSTATIC	MC/DEL		AMICAR						
	MC		AMINOCAPROIC ACID						
OPHTHALMICS									
OP. - ANTIBIOTICS	MC		AK-SPORE OINT	MC		AK-POLY-BAC OINT	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered	
	MC		BACITRACIN OINT	MC		AK-SULF OINT		on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the	

	MC	1	LUMIGAN SOLN				products must be used in specified step order or PA required. Use PA Form # 20420	significant potential drug interaction between another drug and the preferred drug(s) exists.
OP. - CYCLOPLEGICS	MC MC/DEL MC/DEL MC/DEL		AK-PENTOLATE SOLN ATROPINE SULFATE CYCLOPENTOLATE HCL SOLN ISOPTO HYOSCINE SOLN	MC/DEL MC MC/DEL MC		CYCLOGYL SOLN ISOPTO ATROPINE SOLN ISOPTO HOMATROPINE SOLN MUROCOLL-2 SOLN	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
OP. - MIOTICS - DIRECT ACTING	MC/DEL MC MC MC/DEL MC/DEL		ISOPTO CARBACHOL SOLN ISOPTO CARPINE SOLN PILOCAR SOLN PILOCARPINE HCL SOLN PILOPINE HS GEL					
OP. - ADRENERGIC AGENTS	MC/DEL MC		DIPIVEFRIN HCL SOLN EPIFRIN SOLN	MC		PROPINE SOLN	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
OP. - SELECTIVE ALPHA ADRENERGIC AGONISTS	MC MC		ALPHAGAN SOLN ALPHAGAN P SOLN	MC/DEL		LOPIDINE SOLN	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
OP. - ANTI-ALLERGICS	MC MC/DEL		ELESTAT PATANOL SOLN	MC MC/DEL MC/DEL MC MC/DEL		ALOCRIL SOLN ALOMIDE SOLN EMADINE SOLN LIVOSTIN SUSP OPTICROM SOLN ZADITOR SOLN	Use PA Form # 20420	All preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
OP. ANTI-ALLERGICS- MASTCELL STABILIZER CLASS	MC/DEL		ALAMAST SOLN					
OP. - CARBONIC ANHYDRASE INHIBITORS/COMBO	MC/DEL MC/DEL MC/DEL		AZOPT SUSP COSOPT SOLN TRUSOPT SOLN					
OP. - NSAID'S	MC MC MC MC		ACULAR LS ACULAR SOLN FLURBIPROFEN SODIUM SOLN VOLTAREN SOLN	MC		OCUFEN SOLN	Must fail all preferred products before non-preferred. Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
OP. - OF INTEREST	MC/DEL		ENUCLENE SOLN	MC MC		BOTOX SOLR RESTASIS ¹	1. Must have kerato conjunctivitis sicca and failed other dry eye therapies. Use PA Form #20420	Must fail adequate trials of multi agents from artificial tears and lubricant category.
DERMATOLOGICAL								
TOPICAL - ACNE PREPARATIONS	MC/DEL MC MC MC MC/DEL MC MC MC/DEL MC MC MC MC/DEL MC MC MC MC/DEL		ACCUTANE CAPS AKNE-MYCIN OINT AZELEX CREA BENZOYL PEROXIDE CLEOCIN-T DIFFERIN ERYDERM SOLN ERYTHROMYCIN GEL ERYTHROMYCIN PADS ERYTHROMYCIN SOLN METROCREAM CREA METROGEL GEL METROLOTION LOTN PLEXION RETIN-A CREA ² RETIN-A GEL ² RETIN-A LIOD ² SODIUM SULFACET/SULF LOTN	MC MC MC MC/DEL MC/DEL MC/DEL MC MC MC MC MC/DEL MC MC MC MC/DEL MC MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL		ALTNAC CREA AVITA CREA BENZAC BENZACLIN GEL BENZAGEL-10 GEL BENZAMYCIN GEL BENZAMYCINPAK PACK BREVOXYL CLINAC BPO GEL CLINDAGEL GEL CLINDAMYCIN PHOSPHATE CLINDETS SWAB DESQUAM-E GEL DESQUAM-X DUAC GEL EMGEL GEL ERYCETTE PADS ERYGEL GEL FINEVIN CREA KLARON LOTN NORITATE CREA RETIN-A MICRO GEL SULFACET-R LOTN TRETINOIN TRIAZ ZETACET	2. For these Retin-A products, over 24 yr. need PA. Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
TOPICAL - ANTIBIOTIC	MC MC/DEL MC/DEL MC/DEL		BACIT/NEOMYCIN/POLYM OINT BACITRACIN OINT BACTROBAN ¹ CENTANY OINT 2% ¹	MC MC/DEL MC/DEL		CORTISPORIN TRIPLE ANTIBIOTIC OINT	1. Quantity limit of 30 g per month. Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.

	MC/DEL MC MC/DEL	CLOBETASOL PROPIONATE ULTRAVATE PSORCON				
	MC MC MC	MISCELLANEOUS CAPEX SHAM DERMA-SMOOTHIE/FS OIL PROCTO-KIT CREA				
TOPICAL - STEROID LOCAL ANESTHETICS	MC/DEL MC	PRAMOSONE ZONE-A FORTE LOTN	MC		EPIFOAM FOAM	Use PA Form # 20420 Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
TOPICAL - STEROID COMBINATIONS	MC	DERMA-SMOOTHIE/FS ATOPIC P KIT	MC		CARMOL-HC CREA	Use PA Form # 20420 Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
TOPICAL - EMOLLIENTS	MC/DEL MC MC MC MC MC	AMLACTIN CREA CETAPHIL GENTLE CLEANSER LOTN LAC-HYDRIN LACTINOL-E CREA UREACIN-20 CREA VITAMIN A & D MEDICATED OINT	MC/DEL MC/DEL MC/DEL MC MC		AMMONIUM LACTATE CREA LACLOTION LOTN LACTINOL LOTN MEDERMA GEL RENOVA CREA	Use PA Form # 20420 Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
TOPICAL - ENZYMES / KERATOLYTICS / UREA	MC MC/DEL MC MC MC MC	GRANUL-DERM AERS GRANULEX AERS PANAFIL OINT PAPAIN-UREA-CHLORO OINT TBC AERS XENADERM OINT	MC MC MC MC MC		CARMOL 40 CREA SANTYL OINT SALEX CREAM SALEX LOTION ZIOX OINT	Use PA Form # 20420 Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
TOPICAL - GENITAL WARTS	MC/DEL	ALDARA	MC/DEL MC/DEL	5 8	PODOFILOX SOLN CONDYLOX	Non-preferred products must be used in specified order. Use PA Form # 20420
TOPICAL - IMMUNOMODULATORS			MC/DEL	8 9	ELIDEL CREA PROTOPIC OINT	Non-preferred products must be used in specified order. The FDA has issued a Public Health Advisory for both Elidel and Protopic concerning the potential cancer risk associated with their use. Use for children less than 2 years of age is not recommended. Use PA Form # 20420 Preferred corticosteroids from other classes must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. Approvals will be made for small amounts of non-preferred products for the treatment of very steroid-sensitive areas in conjunction with topical steroids for the treatment of atopic dermatitis.
TOPICAL - LOCAL ANESTHETICS	MC MC/DEL MC MC/DEL MC/DEL MC/DEL	AF CAPSICUM OLEORESIN CREA CAPSAICIN CREA ELA-MAX ¹ EMLA CREA ¹ EMLA/TEGADERM KIT ¹ XYLOCAINE	MC/DEL MC MC/DEL MC MC MC		EMLA PADS LIDA MANTLE CREA LIDOCAINE HCL LIDODERM PTCH PONTOCAINE SOLN ZOSTRIX	1. Emla and Ela-Max products require PA for users over 18 years of age. Use PA Form # 20420 Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
TOPICAL - DEPIGMENTING AGENTS			MC MC MC/DEL MC/DEL MC MC MC	8 8 8 8 8 8 9	ALUSTRA CREA GLYQUIN CREA HYDROQUINONE CREA HYDROQUINONE/SUNSCREENS SOLAQUIN FORTE CREA TRI-LUMA CREA ELDOQUIN	Not covered for cosmetic purposes. Use PA Form # 20420 As per Medicaid Policy, cosmetic drugs are not covered. Non-cosmetic clinical applications will be considered by prior authorization on a case by case basis.
TOPICAL - SCABICIDES AND PEDICULICIDES	MC/DEL MC MC MC MC/DEL MC MC/DEL	ACTICIN CREA ELIMITE CREA EURAX LICE KILLING SHAM LICE TREATMENT CREME RINS LIOD NIX CREME RINSE LIOD PERMETHRIN LOTN	MC/DEL MC		LINDANE OVIDE LOTN	Use PA Form # 20420 Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
TOPICAL - WOUND / DECUBITUS CARE	MC MC MC/DEL	ACCUZYME OINT ACCUZYME SPRAY ETHEZYME	MC		REGRANEX GEL	Use PA Form # 20420 Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists. Regranex will be approved for diabetic patients in good control (HgbA1c <8), who are not smoking, with a stage III or IV WOCN AND NPUAP lower extremity diabetic ulcer and with an adequate blood supply (TcP 02 >30, ABI >0.7 or ASP > 70), and where the underlying cause has been corrected. The wound must be free of infection and have been previously treated with preferred standard therapies for at least 2 months. Maximum approval for 20 weeks.
TOPICAL - ASTRINGENTS / PROTECTANTS	MC MC MC	ALUMINUM CHLORIDE SOLN DRYSOL SOLN XERAC AC SOLN	MC MC MC MC		LOWILA BAR MOISTURIN DRY SKIN CREA PROSHIELD PLUS SKIN PROTE CREA SURGILLUBE GEL	Use PA Form # 20420 Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
TOPICAL - ANTISEPTICS /	MC	HIBICLENS LIOD	MC		BETADINE OINT	Use PA Form # 20420 Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved.

DISINFECTANTS		MC/DEL MC/DEL	PHISOHEX LIQD POVIDONE-IODINE SOLN	MC MC MC	FORMALDEYDE-10 AERS IODOSORB LAZERFORMALYDE SOLUTION SOLN		unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.	
MISCELLANEOUS EYE								
OP. - EYE		MC MC MC MC MC/DEL	AK-DILATE SOLN EYE WASH SOLN NAPHAZOLINE HCL SOLN PHENYLEPHRINE HCL SOLN PONTOCAINE SOLN SODIUM CHLORIDE	MC MC/DEL MC	LENS PLUS REWETTING DROPS MURO 128 NEO-SYNEPHRINE SOLN	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.	
MISCELLANEOUS EAR								
EAR		MC/DEL MC MC/DEL MC/DEL MC/DEL MC/DEL MC MC/DEL MC MC/DEL MC MC/DEL MC MC/DEL MC MC/DEL MC MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL	A/B OTIC SOLN ACETASOL SOLN ACETIC ACID ACETIC ACID/HYDROCORTISON ALLERGEN SOLN ANTIPYRINE/BENZOCAINE SOLN AURODEX SOLN AUROGUARD SOLN AUROTO OTIC SOLN CERUMENEX SOLN CIPRODEX CORTISPORIN SOLN CORTOMYCIN EAR DROPS SOLN EAR DROPS RX SOLN EAR WAX REMOVAL DROPS EAR-GESIC SOLN FLOXIN OTIC SOLN NEOMYCIN/POLYMYXINHC OTICAINE OTIC SOLN	MC/DEL MC MC MC MC MC/DEL MC MC MC/DEL MC/DEL MC MC MC/DEL MC MC MC/DEL MC MC/DEL MC MC/DEL MC/DEL MC/DEL MC/DEL	ACETASOL HC SOLN AERO OTIC HC SOLN ANTIBIOTIC EAR SOLN ANTIBIOTIC EAR SUSP AURALGAN SOLN CIPRO HC SUSP COLY-MYCIN-S SUSP CORTISPORIN SUSP CORTISPORIN-TC SUSP DEBROX SOLN DOMEBORO SOLN PEDIOTIC SUSP VOSOL-HC SOLN ZOTANE HC SOLN ZOTO-HC SOLN	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.	
MOUTH ANTISEPTICS								
MOUTH ANTI-INFECTIVES		MC MC MC/DEL	NILSTAT SUSP EAR-GESIC SOLN NYSTATIN SUSP	MC MC MC	MYCELEX TROC MYCOSTATIN LOZG	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.	
MOUTH ANTISEPTICS		MC/DEL MC/DEL MC MC	CHLORHEXIDINE GLUCONATE LIDOCAINE VISCOUS SOLN TRIAMCINOLONE IN ORABASE PSTE TRIAMCINOLONE ORADENT PSTE	MC MC MC MC	APHTHASOL PSTE PERIDEX SOLN PERIOGARD SOLN TRIAMCINOLONE ACETONIDE PSTE XYLOCAINE VISCOUS SOLN	Must fail all preferred products before non-preferred. Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.	
DENTAL PRODUCTS								
DENTAL PRODUCTS		MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC	ETHEDENT CREA GEL-KAM CONC PHOS FLUR SOLN PREVIDENT PREVIDENT SOLN SF GEL STANNOUS FLUORIDE ORAL RI CONC	MC/MC MC/DEL MC/DEL MC/DEL MC	APF GEL GEL DENTAGEL GEL PHOS-FLUR GEL SF 5000 PLUS CREA THERA-FLUR-N GEL	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.	
ARTIFICIAL SALIVA/STIMULANTS								
ARTIFICIAL SALIVA/STIMULANTS		MC MC	EVOXAC CAPS SALIVA SUBSTITUTE SOLN	MC MC	RADIACARE SOLR SALAGEN TABS	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.	
MISCELLANEOUS ANORECTAL								
ANORECTAL - MISC.		MC/DEL MC/DEL MC MC MC/DEL MC/DEL	ANALPRAM-HC CREA COLOCORT ENEM CORTENEMA ENEM ELA-MAX 5 CREA HYDROCORTISONE ENEM PROCTOZONE-HC CREA	MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL MC/DEL	ANUSOL-HC CREA CORTIFOAM FOAM PROCTOCREAM-HC CREA PROCTOFOAM HC FOAM PROCTO-KIT CREA PROCTOSOL HC CREA	Use PA Form # 20420		
T-CELL ACTIVATION INHIBITOR								
PSORIASIS BIOLOGICALS				MC MC MC	5 8 8	ENBREL AMEVIVE RAPTIVA	Use PA Form # 20910	Approved for severe chronic plaque psoriasis unresponsive to first line therapies. A trial of at least several potent topicals from the following categories: corticosteroids, coal tars, anthralin, calcipotriene and tazarotene, and at least one systemic drug such as methotrexate, cyclosporine, methoxsalen or acitretin and phototherapy/UVA. High dose Enbrel will be approved for chronic severe psoriasis only after failure of all traditional therapies listed here and adequate trial of either Amevive or Raptiva.
ALTERNATIVE MEDICINES								
ALTERNATIVE MEDICINES		MC	DIMETHYL SULFOXIDE SOLN	MC MC/DEL MC MC MC	ARTHX DS CAPS CO-ENZYME Q-10 DEHYDROEPIANDOSTERONE DHEA TABS FLEXAGEN TABS	Use PA Form # 20420	Will only be approved for specific conditions supported by at least two double-blinded, placebo-controlled randomized trials that are not contradicted by other studies of similar quality.	

			MC/DEL MC MC	GLUCOSAMINE/CHONDROITIN HM GINKGO BILOBA TABS MELATONIN TABS		
CHELATING AGENTS						
CHELATING AGENTS	MC/DEL	CUPRIMINE CAPS	MC	DEPEN TITRATABS TABS	Use PA Form # 20420	
ANTILEPROTIC						
ANTILEPROTIC			MC	THALOMID CAPS	Use PA Form # 20420	Approved for indications of leprosy, treatment-resistant multiple myeloma and AIDS.
CANCER						
CANCER	MC MC/DEL MC MC/DEL	ALIMTA AVASTIN ERBITUX VIDAZA				
IMMUNOSUPPRESSANTS						
IMMUNOSUPPRESSANTS	MC/DEL MC/DEL MC/DEL MC MC/DEL MC MC/DEL MC/DEL	CELLCEPT CYCLOSPORINE MODIFIED CYCLOSPORINE SOL. MODIFIED GENGRAF CAPS MYFORTIC PROGRAF CAPS RAPAMUNE SANDIMMUNE	MC/DEL MC/DEL	CYCLOSPORINE CAPS NEORAL ^{1,2}	1. Established users will require a one time PA. 2. Established users will require a one time PA Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
PURINE ANALOG						
PURINE ANALOG	MC MC/DEL	AZASAN TABS AZATHIOPRINE TABS	MC/DEL	IMURAN TABS	Use PA Form # 20420	Preferred drugs must be tried and failed due to lack of efficacy or intolerable side effects before non-preferred drugs will be approved, unless an acceptable clinical exception is offered on the Prior Authorization form, such as the presence of a condition that prevents usage of the preferred drug or a significant potential drug interaction between another drug and the preferred drug(s) exists.
K REMOVING RESINS						
K REMOVING RESINS	MC/DEL MC MC/DEL MC/DEL MC/DEL	KAYEXALATE POWD KIONEX POWD SODIUM POLYSTYRENE SULFON SPS SUSP SPS 30GM/120ML ENEMA SUSP			Use PA Form # 20420	

New drugs are initially non-preferred until reviewed by the DUR Committee and the State. According to State policy, any drug requiring specific diagnosis still requires the specific diagnosis unless otherwise noted within this document.

IVULSANTS INDICATION CHART

	SEIZURES	POST HERPETIC NEURALGIA	DIABETIC PERIPHERAL NEUROPATHY	MONOTHERAPY BIPOLAR	ADJUNCTIVE BIPOLAR	MIGRAINE PROPHYLAXIS	RESTLESS LEG SYNDROME
GABITRIL	X			9	8		
KEPPRA	X			9	7		
LAMICTAL	X			4	4		
LYRICA	X	X(2 nd line)	X(2 nd line)				
NEURONTIN	X	X(2 nd line)	X (2 nd line)	9	9	X (2 nd line)	X (2 nd line)
TOPAMAX	X			9	6	X (2 nd line)	
TRILEPTAL	X			5	5		
ZONEGRAN	X			9	9		

TI-CONVULSANTS INDICATION CHART

	SEIZURES	MONOTHERAPY BIPOLAR	ADJUNCTIVE BIPOLAR
LITHIUM		1	1
CARBMAZEPINE	X	1	1
VALPROATE	X	1	1
ATYPICAL ANTIPSYCHOTICS EXC. CLOZAPINE	X	1	1
LAMICTAL	X	1	1
TRILEPTAL	X	5	5
CLOZAPINE	X	6	6